Cardiac complications in patients with COVID-19: a systematic review

E. Brogi1,*, F. Marino2,3, P. Bertini4, G. Tavazzi5,6, F. Corradi2,7 and F. Forfori2

Abstract

Cardiac complications in patients with COVID-19 have been described in the literature with an important impact on outcome. The primary objective of our systematic review was to describe the kind of cardiac complications observed in COVID-19 patients and to identify potential predictors of cardiovascular events. The secondary aim was to analyze the effect of cardiac complications on outcome.

We performed this systematic review according to PRISMA guidelines using several databases for studies evaluating the type of cardiac complications and risk factors in COVID-19 patients. We also calculated the risk ratio (RR) and 95% CI. A random-effects model was applied to analyze the data. The heterogeneity of the retrieved trials was evaluated through the $I^2$ statistic. Our systematic review included 49 studies. Acute cardiac injury was evaluated in 20 articles. Heart failure and cardiogenic shock were reported in 10 articles. Myocardial infarction was evaluated in seven of the papers retrieved. Takotsubo, myocarditis, and pericardial effusion were reported in six, twelve, and five articles, respectively. Arrhythmic complications were evaluated in thirteen studies. Right ventricular dysfunction was evaluated in six articles. We included 7 studies investigating 2115 patients in the meta-analysis. The RR was 0.20 (95% CI: 0.17 to 0.24; $P < 0.00001$, $I^2 = 0.75$). Acute cardiac injury represented the prevalent cardiac complications observed in COVID-19 patients (from 20 to 45% of the patients). Patients with acute cardiac injury seemed to be significantly older, with comorbidities, more likely to develop complications, and with higher mortality rates. Acute cardiac injury was found to be an independent risk factor for severe forms of SARS-CoV-2 infection and an independent predictor of mortality. Due to the scarce evidence, it was not possible to draw any conclusion regarding Takotsubo, myocarditis, pleural effusion, and right ventricular dysfunction in COVID-19 patients.

Noteworthy, possible arrhythmic alterations (incidence rate of arrhythmia from 3 to 60%) in COVID-19 patients have to be taken into account for the possible complications and the consequent hemodynamic instabilities. Hypertension seemed to represent the most common comorbidities in COVID-19 patients (from 30 to 59.8%). The prevalence of cardiovascular disease (CVD) was high in this group of patients (up to 57%), with coronary artery disease in around 10% of the cases. In the majority of the studies retrieved, patients with CVD had a higher prevalence of severe form, ICU admission, and higher mortality rates.

Keywords: Acute myocardial injury, Acute myocardial infarction, Acute cardiac injury, Cardiac complications, Heart failure, Arrhythmia, Mortality, Coronavirus, Coronavirus infection
Background
From December 2019, when a new severe respiratory disease was reported in Wuhan, China, the infection caused by a novel coronavirus quickly spread across the globe causing a pandemic with devastating consequences [1] and challenging health care organization [2].

Although COVID-19 is characterized mainly by upper and lower respiratory system involvement, with consequent respiratory symptoms at different grades of severity (from cough to shortness of breath, to dyspnea, to respiratory failure), evidence of extrapulmonary manifestations is established [3–5] including venous and arterial thrombotic manifestations [6, 7]. Cardiac complications (i.e., acute cardiac injury, cardiogenic shock, heart failure, arrhythmia, right ventricular dysfunction) have been described in the literature with an important impact on outcome [8]. Several mechanisms are implicated in the genesis of cardiac complications in patients with COVID-19: direct myocardial cells injury (through ACE2 receptors), systemic inflammation, catecholamine surge, cytokine storm, electrolyte imbalance, and hypoxia [9]. Consequently, it was extremely important to further report the cardiological events related to COVID-19 and identify possible risk factors (e.g., hypertension, diabetes) in order to stratify patients with increased risk of cardiovascular events during SARS-CoV-2.

The primary objective of our systematic review was to describe the type of cardiac complications in patients with COVID-19 and the potential associated risk factors (i.e., hypertension, diabetes, previous stroke, previous cardiovascular events, respiratory diseases, COPD, malignancy, chronic kidney disease, chronic liver disease) that may allow the identification of patients more exposed to cardiovascular events represented our secondary aim. The secondary aim was to analyze the relation between cardiac complications and outcome.

Methods
Protocol and registration
The authors performed this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements [10].

PROSPERO registration number: CRD42021231922.

Search
We systematically explored the US National Library of Medicine database (MEDLINE), Web of Science, Google Scholar, Scopus, Cinhal Database, and Cochrane Central Register of Controlled clinical studies (CENTRAL) for RCT, case report, case series, letters to the editor, correspondence, abstracts, and brief reports from 2019 to 2021. We did not impose any restrictions for language. The search criteria were (arrhythmia OR cardiac ischemia OR cardiogenic shock OR acute myocardial infarction OR Heart failure OR Myocarditis OR right ventricle dysfunction) AND (COVID-19 OR coronavirus OR coronavirus pandemic OR coronavirus pneumonia) AND (comorbidities OR hypertension OR Diabetes OR dyslipidemia OR smoker OR chronic obstructive pulmonary disease OR COPD OR chronic kidney disease OR chronic kidney failure OR stroke OR Chronic liver failure OR hyperthyroidism OR dementia). Furthermore, we hand-searched the reference lists of the articles in order to find all relevant articles missed by electronic search. The research was limited to randomized, observational, and retrospective studies, case report, case series, letters to the editor, correspondence, abstracts, and brief reports on human subjects that describe the type of cardiac complications in COVID patients and the possible clinical factors that may allow the identification of patients with a high risk of cardiovascular events.

Eligibility and study selection
We included randomized, case-controlled, and cohort studies (both prospective and retrospective), case report, and case series evaluating the type of cardiac complications in COVID-19 patients and the possible clinical risk factors. Reviews, conference proceedings, meta-analyses, and international expert recommendations were not included. The authors screened all search results, titles, and abstracts of retrieved articles to assess eligibility and then obtained a full-length manuscript for all the included studies. Among the publications identified, we excluded studies of irrelevance to the topic, technical descriptions, proceeding, and non-human model studies.

Data collection
A data collection form was created with the following main study characteristics: authors, year of publication, country, number of patients included, study design, primary outcome, other outcomes, number of treatment/control, inclusion criteria, exclusion criteria, quality of the evidence, age, sex, cardiovascular comorbidities, other comorbidities, COVID-19 severity, characteristics of cardiac complication analyzed, other cardiological complications (respiratory, neurological, infections), and outcomes. The authors screened all search results by literature search. One investigator (F.M.) was in charge of collecting the data and assessing the methodological validity of all the eligible studies. Then, all the data were verified by two further investigators (E.B., F.F.).

Outcome
The primary objective was to describe the type of cardiac complications observed in COVID-19 patients and to identify possible clinical risk factors (i.e., hypertension, diabetes, dyslipidemia, smoking, coronary heart...
disease previous stroke, previous cardiovascular events, respiratory diseases, COPD, malignancy, chronic kidney disease, chronic liver disease) that may allow the identification of patients with a high risk of cardiovascular complications in comparison with patients without risk factors. The secondary aim was to analyze the effects of cardiac complications on mortality.

Assessment of study quality
For randomized studies, the selected articles were evaluated using the 3-item, 5-point Oxford Quality Scale. Studies are rated on the basis of three methodological features: 2 points for descriptions of randomization, 2 points for the description of the blinding process, and 1 point for the description of withdrawal. We excluded from this review all articles which did not obtain a minimum score of 2. The Newcastle-Ottawa Scale was used for case-controlled or cohort studies quality assessment. Each study is judged on three broad perspectives: the choice of the study groups, the comparability of the groups, and also the ascertainment of either the exposure or the outcome of interest for case-control or cohort studies, respectively.

Strategy for data synthesis
We created a descriptive summary table with the main characteristics of included studies (Table 1). Then, we also created descriptive tables for the following cardiac complications (from Tables 2, 3, 4, 5, and 6; a graphical representation of the cardiac complications is shown in Fig. 1):

1. Acute cardiac injury
2. Acute myocardial infarction
3. Takotsubo syndrome
4. Myocarditis
5. Pericardial effusion
6. Arrhythmias
7. Right ventricular dysfunction

For all patients who were reported to have cardiovascular complications, we analyzed demographics (age, sex), risk factors/comorbidities, clinical features (cardiac biomarkers, ECG, and/or echocardiographic findings), and their relation with outcome. A major limitation of this review includes the heterogeneity in cardiac injury definition (ECG/biomarkers). The authors of this systematic review reported the definition provided by the authors for each article included.

Statistical analysis
The Cochrane handbook for systematic reviews of interventions [59] and Hozo and coll [60]. recommendations were followed in order to perform the meta-analysis. Secondary outcome data were extracted only from the published articles retrieved. Publication bias was evaluated by analyzing the funnel plots. We calculated risk ratio (RR) and 95% confidence interval (CI) to summarize continuous data. A random-effects model was applied to analyze the data. The heterogeneity of the retrieved trials was evaluated through the $I^2$ statistic. $I^2$ values above 75% reflected a high heterogeneity [61, 62]. Subgroup analyses were performed as sensitivity analysis according to the type of cardiac complications (acute cardiac injury, cardiogenic shock, heart failure, arrhythmia, right ventricular dysfunction). All statistical analyses were performed using Review Manager (RevMan; Computer program. Version 5.3 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012).

Results
Electronic literature searches identified 605 articles, and 16 further citations were found by hand searching the reference lists of the studies. We initially excluded articles as not relevant for the aim of the review basing on the abstract. We selected 78 articles for full-text review. Twenty-nine studies were further excluded for one of the following reasons: outcome was not reported, preliminary studies, and technical descriptions. Our review finally included 49 clinical studies (Fig. 2). Study characteristics and outcomes are listed in Table 1.

The current study was performed between January and September.

Twenty-two articles (%) were conducted by Chinese groups [15–17, 19, 22, 23, 25–27, 39, 42–44, 50–58], nine (%) were carried out in the USA [11–14, 18, 28, 33, 38, 49], thirteen (%) were from European groups [20, 21, 24, 29, 34–37, 40, 45, 46, 48, 63], two (%) from Korea [30, 31], and one (%) respectively from Trinidad and Tobago [41], Israel [47], and India [32]. Twenty-three articles (%) were case reports or case series [11–14, 18, 20, 21, 26, 28–31, 34–38, 40, 41, 45, 48, 49, 55], twenty (%) were retrospective in nature [15–17, 19, 22, 25, 27, 33, 39, 42–44, 46, 50–53, 56–58], five (%) prospective studies [23, 32, 47, 54, 63], and one international survey [24]. Quality assessments for the included trials are reported in Table 1. The first aim of twenty-seven studies was the description of cardiovascular manifestation in patients with COVID-19 [11, 13, 16, 19, 21, 25, 26, 28, 30–35, 37, 38, 40, 41, 43–46, 48, 49, 51, 55]. The majority of these trials highlighted the impact of COVID-19 on the cardiovascular system and the need for continuous monitoring and prompt treatment. The evaluation of echocardiography was the first aim of one international survey [24] and two prospective studies [47, 63]. Echocardiographic abnormalities were observed in more than half of COVID-19 patients included. The description of the clinical characteristics and/or outcome of patients with
| Authors            | Month/year of publication | Country | Study design | Primary outcome                                           | Other outcomes                                                                 | All patients | No. of treatment/control | Inclusion criteria | Exclusion criteria | Quality of evidences |
|--------------------|---------------------------|---------|--------------|-----------------------------------------------------------|-------------------------------------------------------------------------------|--------------|---------------------------|-------------------|-------------------|----------------------|
| Amaratunga et al.  | May 2020                   | USA     | Case series  | To report sinus bradycardia as a potential manifestation of COVID-19 | -Association between heart rate and temperature/blood pressure/oxygen saturation
-Association between heart rate and medication | 4            | NA           | NA                | NA               | NA                   |
| Arentz et al.      | March 2020                 | USA     | Case series  | To describe the clinical presentation, characteristics, and outcomes of patients COVID-19 admitted in Evergreen Hospital’s ICU | NA                                                                         | 21           | NA           | NA                | NA               | NA                   |
| Bangalore et al.   | April 2020                 | USA     | Case series  | To describe clinical experience                            | Electrocardiographic evidence                                                | 18           | 8/10         | Patients with STEMI | NA               | NA                   |
| Barton et al.      | June 2020                  | USA     | Case series: autopsy | To share observations on COVID-19, based on 2 autopsies | To share experience on precautions and equipment to perform autopsies           | 2            | NA           | -Patients not treated for COVID-19
-Not tested patients before death | NA               | NA                   |
| Cao et al.         | March 2020                 | China   | Retrospective | To describe therapies, clinical and laboratory characteristics, and short-term outcomes of COVID-19 patients admitted in ICU | NA                                                                         | 102          | 18–84        | Patients with COVID-19 hospitalized in Wuhan University Zhongnan Hospital between January 3 and February 1, 2020 | NA               | 7#                   |
| Chen et al.        | May 2020                   | China   | Retrospective | To identify how COVID-19 damages the cardiovascular system, at the level myocardial, conduction system, heart function, and blood pressure, especially in severe cases | To highlight potential risk factors for the severity of COVID-19 | 54           | NA           | Severe and critical clinical cases, hospitalized in Zhongshan hospital between January 27 and February 28, 2020 | NA               | 7#                   |
| Chen et al.        | May 2020                   | China   | Retrospective | Comparing the demographic, clinical, laboratory, and radiological characteristics of patients with different clinical outcomes | NA                                                                         | 274          | 113–161      | Patients admitted to the Tongji Hospital between January 13 and February 12, 2020, who died or discharged until February 28, 2020 | NA               | 7#                   |
| Dabbagh et al.     | April 2020                 | USA     | Case report  | Description of a clinical case                              | NA                                                                         | 1            | NA           | NA                | NA               | NA                   |
| Deng et al.        | April 2020                 | China   | Retrospective | To investigate COVID-19 patients’ clinic and therapy, focusing on heart condition | To provide information about possible myocarditis or myocardial injury caused by COVID-19 | 112          | 45/67        | Patients admitted between January 6 and February 20, 2020, diagnosed with COVID-19 at Renmin Hospital in Wuhan | NA               | 7#                   |
| Dominguez-Equieia et al. | May 2020             | Spain   | Case Report  | Report                                                     | NA                                                                         | 1            | NA           | NA                | NA               | NA                   |
| Doyen et al.       | April 2020                 | France  | Clinical case | Report                                                     | NA                                                                         | 1            | NA           | NA                | NA               | NA                   |
| Du et al.          | April 2020                 | China   | Retrospective | Describe clinical features                                 | NA                                                                         | 85           | NA           | All consecutive patients with severe COVID-19 admitted to Hannan Hospital and Wuhan Union Hospital between January 9 and February 15, 2020 | NA               | 7#                   |
| Authors          | Month/year of publication | Country   | Study design                  | Primary outcome                                                                 | Other outcomes                                      | All patients | No. of treatment/control | Inclusion criteria                                                                 | Exclusion criteria                                   | Quality of evidences |
|------------------|---------------------------|-----------|-------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------|--------------|-------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------|---------------------|
| Du et al. [23]   | April 2020                | China     | Multicenter observational study | To describe hospitalization and critical care of patients who died of COVID-19 pneumonia | NA                                                  | 109          | 51/58                   | NA                                                                               | NA                                                                  | 7#                  |
| Dweck et al. [24] | September 2020            | UK        | International survey          | To improve knowledge about cardiac manifestations of COVID-19                    | To find patients who would benefit most from echocardiography | 1216         | 667/549                 | Patients with confirmed or a high probability of COVID-19 with collected transthoracic echocardiogram in hospital setting from April 3 to April 20, 2020 | Not available data                                                | 7#                  |
| Guo et al. [25]  | July 2020                 | China     | Retrospective                 | To investigate the association between cardiovascular disease and myocardial injury with fatal outcomes | NA                                                  | 187          | 135/52                  | Patients with a diagnosis of COVID-19, according to the guidance of WHO, admitted to the Seventh Hospital of Wuhan City, China, from January 23 to February 23, 2020 | Incomplete data                                             | 7#                  |
| Hu et al. [26]   | March 2020                | China     | Case report                   | Helpful in treating similar patients                                             | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Huang et al. [27] | January 2020              | China     | Report of data                | To describe epidemiological, clinical, laboratory, and radiological characteristics, treatment, and outcomes of patients confirmed with COVID-19 | To compare ICU and non-ICU patients                  | 41           | 13/28                   | NA                                                                               | NA                                                                  | 7#                  |
| Hussain et al. [28] | June 2020               | USA       | Case report                   | Report                                                                           | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Inciardi et al. [29] | March 2020            | Italy     | Case report                   | To describe the presentation of acute myocarditis in patients with COVID-19     | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Kim HN et al. [30] | June 2020               | Korea     | Case report                   | To present their first case of PCI for a patient with COVID-19                   | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Kim IC et al. [31] | April 2020              | Korea     | Case report                   | Report                                                                           | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Kunal et al. [32] | November 2020            | India     | Retrospective                 | To evaluate the cardiovascular complications and their impact on outcomes         | NA                                                  | 108          | 28/80                   | Symptomatic laboratory-confirmed COVID-19                                       | Asymptomatic patients No cardiac documentation            | 7#                  |
| Kuno et al. [33] | May 2020                 | USA       | Retrospective                 | To investigate the relation between cardiovascular disease and mechanical ventilation and mortality | NA                                                  | 8438         | NA                      | COVID-19 patients                                                               | NA                                                                  | 6#                  |
| Meyer et al. [34] | April 2020               | Switzerland | Case report               | Description of Takotsubo case                                                    | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Monnemeu et al. [35] | May 2020                 | Spain     | Case report                   | To provide evidence obtained with CMR of extensive myocardial involvement secondary to SARS-CoV2 infection | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Pascariello et al. [36] | June 2020               | Italy     | Case report                   | To describe a case of cardiogenic shock due to COVID-19-related myocarditis     | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Paul et al. [37]  | July 2020                | France    | Case report                   | Report                                                                           | NA                                                  | 1            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Peigh et al. [38] | April 2020               | USA       | Case series                   | To describe clinical characteristics, potential mechanisms, and outcomes of COVID-19 patients who develop de novo sinus node dysfunction | NA                                                  | 2            | NA                      | NA                                                                               | NA                                                                  | NA                  |
| Authors            | Month/ year of publication | Country          | Study design | Primary outcome                                                                 | Other outcomes                                                                                     | All patients | No. of treatment/ control | Inclusion criteria                                                                 | Exclusion criteria | Quality of evidences |
|--------------------|-----------------------------|------------------|--------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------|----------------------------|-------------------------------------------------------------------------------------|------------------|---------------------|
| Ruan et al. [39]   | March 2020 China            | Retrospective    | To identify clinical predictors of mild and severe patient outcome               | NA                                                                                              | 150 68/82 NA                                                                                      | NA           | NA                         | NA                                                                                  | NA               | 6#                  |
| Sala et al. [40]   | April 202 Italy             | Case report      | Report                                                | NA                                                                                              | 1 NA NA                                                                                           | NA           | NA                         | NA                                                                                  | NA               | NA                  |
| Seecheran et al. [41] | April 2020 Trinidad and Tobago | Case report   | Description                                          | NA                                                                                              | 1 NA NA                                                                                           | NA           | NA                         | NA                                                                                  | NA               | NA                  |
| Shao et al. [42]   | May 2020 China              | Retrospective    | To describe COVID-19 progression and risk profiles for mortality in non-survivors | NA                                                                                              | 18 NA                                                                                             | NA           | NA                         | Patients died from 155 patients who met the criteria of COVID-19 clinical diagnosis based on the National Health Commission of China Guidelines (7th edition) | Patients discharged | 7#                  |
| Shi et al. [43]    | July 2020 China             | Retrospective cohort | To examine the association between cardiac injury and mortality               | NA                                                                                              | 416 82/334 Consecutive patients admitted to Renmin Hospital with confirmed COVID-19, according to WHO interim guidance | NA           | NA                         | No record of cardiac markers                                                                                     | NA               | 7#                  |
| Shi et al. [44]    | May 2020 China              | Retrospective    | To determine the predictive value of myocardial injury markers on hospital death | To investigate features and potential causes of myocardial injury in severe COVID-19 patients   | 671 106/565                                                                                        | NA           | NA                         | Cases with mild COVID-19, duplicated cases, and cases without available medical information | NA               | 7#                  |
| Solano-Lopez et al. [45] | May 2020 Spain             | Case report      | To describe a case of inverted Takotsubo                                       | NA                                                                                              | 1 NA NA                                                                                           | NA           | NA                         | NA                                                                                  | NA               | NA                  |
| Stefanini et al. [46] | June 2020 Italy             | Retrospective    | To evaluate the incidence, clinical presentation, angiography, and outcomes of STEMI in patients with COVID-19 | NA                                                                                              | 28 NA                                                                                             | NA           | NA                         | All patients with confirmed COVID-19 who underwent an urgent angiography because of STEMI between February 20 and March 30, 2020 | NA               | 6#                  |
| Stekler et al. [47] | July 2020 Israel            | Prospective      | Comprehensive echocardiographic evaluation—frequency of cardiac abnormalities | Echocardiographic parameters stratified by troponin levels and clinical condition               | 100 NA                                                                                             | NA           | NA                         | Consecutive patients hospitalized with COVID-19 patients Echocardiographic evaluation not performed | NA               | 6#                  |
| Söbbe et al. [52]  | August 2020 Germany         | Observational study | To characterize the myocardial effects by echocardiography                      | NA                                                                                              | 18 NA                                                                                             | NA           | NA                         | Patients with SARS-CoV-2 admitted at Leipzig University Hospital and at Community Hospital Halle (Saale) in April 2020 | NA               | 7#                  |
| Tavaazzi et al. [48] | April 2020 Italy            | Case report      | To describe a case of myocardial biopsy to prove SARS-CoV-2 localization in myocardium | NA                                                                                              | 1 NA NA                                                                                           | NA           | NA                         | NA                                                                                  | NA               | NA                  |
| Villanueva et al. [49] | June 2020 USA               | Case report      | To describe heart failure and arrhythmia as possible symptoms of COVID-19      | NA                                                                                              | 1 NA NA                                                                                           | NA           | NA                         | NA                                                                                  | NA               | NA                  |
| Wan et al. [50]    | July 2020 China             | Retrospective    | To describe the epidemiological and clinical features, laboratory and radiology findings, and outcomes of COVID-19 patients | NA                                                                                              | 135 95/40                                                                                          | NA           | NA                         | All patients with confirmed COVID-19 admitted to the Chongqing University Three Gorges Hospital from January 23 to February 8, 2020 | NA               | NA                  |
| Xie et al. [51]    | August China                | Retrospective    | To evaluate the effects of cardiovascular                                         | To evaluate                                                                                     | 62 38/24                                                                                          | NA           | NA                         | All patients with confirmed COVID-19 Suspected diagnosis 6# | NA               | 6#                  |
| Authors            | Month/year of publication | Country | Study design                      | Primary outcome                                                                 | Other outcomes                                                                 | All patients | No. of treatment/control | Inclusion criteria                                                                 | Exclusion criteria                  | Quality of evidences |
|--------------------|----------------------------|---------|-----------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------|-------------------------|-----------------------------------------------------------------------------------|--------------------------------------|---------------------|
| Xiong et al. [52]  | October 2020               | China   | Retrospective                     | To provide a recent description of clinical features of patients                | laboratory and clinical characteristics of COVID-19 patients                     | 116          | 61/55                  | admitted to the Hospital from February 15 to March 14, 2020                     | Laboratory Confirmed COVID-19 patients admitted to the General Hospital of Central Theater Command (Wuhan, China) from January 20 to March 8, 2020 | 7°                  |
| Yang et al. [53]   | May 2020                   | China   | Retrospective                     | ICU mortality at 28 days                                                       | Incidence of ARDS and proportion of patients requiring mechanical ventilation   | 52           | 20/32                  | Critical ill patients admitted to Wuhan Jinyintan Hospital from December 24, 2019, to January 26, 2020 | Admission after January 12, 2020, oxygen therapy with FiO2 < 60% | 7°                  |
| Yu et al. [54]     | May 2020                   | China   | Multicenter, prospective, observational study | Evaluation of outcomes and complications and intensity of treatment | NA                                                                            | 226          | NA                     | All patients admitted in ICU from 8 AM of February 26, 2020, to 8 AM of the next day. The ICUs have to have closed adult units, at least 10 beds, full-time physicians and nurses | NA                              | 7°                  |
| Zeng et al. [55]   | April 2020                 | China   | Case report                       | Description                                                                    | NA                                                                            | 1            | NA                     | NA                                                                               | NA                              | NA                  |
| Zhang et al. [56]  | June 2020                  | China   | Retrospective                     | To analyze epidemiological, clinical, laboratory, and radiological features of patients COVID-19 admitted in Zhong’an Hospital of Wuhan University from January 2 to February 10, 2020 | NA                                                                            | 221          | 55/166                 | NA                                                                               | NA                              | 7°                  |
| Zhao et al. [57]   | April 2020                 | China   | Retrospective                     | To explore the characteristics of patients with COVID-19 admitted to Jinyintan Central Hospital from January 16 to February 10, 2020 | NA                                                                            | 91           | 30/61                  | NA                                                                               | NA                              | 7°                  |
| Zhou et al. [58]   | March 2020                 | China   | Retrospective, multicenter        | To explore risk factors of in-hospital mortality                               | To describe clinical and laboratory courses during hospitalization             | 191          | 54/137                 | Adult patients with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital, discharged or died before January 31, 2020 | Patients still hospitalized or not confirmed by COVID-19 and without available data | 7°                  |

Quality of assessment following the 3-item, 5-point Oxford Quality Scale° or the Newcastle-Ottawa Scale# COVID-19
NA not applicable, ICU intensive care unit, STEMI ST-elevation myocardial infarction, WHO World Health Organization, RT-PCR real-time polymerase chain reaction, PCI percutaneous coronary intervention, CMR cardiovascular magnetic resonance, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, ARDS acute respiratory distress syndrome, FiO2 oxygen inspired fraction
## Table 2

Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction”

### Acute cardiac injury

| Authors                  | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiologic comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value | LVEDV – EF (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------------|--------------------------|-----------------------------|---------------------------|---------|-----------------------------------|-----------------------------|-------------------|-----------------------------------------------|-------------------------------------------|-----------------------------|--------------------------------------|--------------------------------|------------------|
| Bangalore et al. [13]    | 63 (54–73)§              | 60 (56–73)§                 | 66 (54–73)§               | 15/3    | Hypertension (11) Diabetes (6) Dyslipidemia (7) Smoking (1) Coronary heart disease (3) | Chronic kidney disease (1) | NA                | 10 TnI 13.5 (4.8–41) ng/ml§ TnT 0.02 ng/ml§ | Not reported (2)           | NA                          | NA                                | Death (4-9)                  |
| Cao et al. [15]          | 54 (37–67)§              | 66 (54–76)§                 | 31 (35–62)§               | 63/49   | Hypertension (28) Diabetes (11) Cardiovascular disease (5) Cerebrovascular diseases (3) | Respiratory diseases (10) Malignancy (4) Chronic kidney disease (4) Chronic liver disease (2) | 6–9                | NA                                      | NA                        | NA                          | NA                                | Shock (10) ARDS (20) Acute infections (17) Acute kidney damage (20) Chronic kidney damage (34) ECMO (3) Mechanical ventilation (7) CRRT (4) ARDS (12-73) Discharge (12-73) |
| Chen et al. [16]         | 57.6 (44.9–70.3)§        | 61.7 ± 13.5°               | 61.7 ± 9.6°               | 36/18   | Hypertension (16) Diabetes (25) Coronary heart disease (6) | NA                           | 0–3               | TnI 0.29 ± 0.68 ng/ml§ NT-proBNP 1582 ± 2374 pg/ml§ | NA                        | AKI (18)                | NA                                | Death (113) Recovered (161) |
| Chen et al. [17]         | 62 (44–70)§              | 68 (62–77)§                 | 51 (37–66)§               | 171/103 | Hypertension (93) Smoke (12) Diabetes (47) Cardiovascular disease (23) Chronic heart failure (1) Cerebrovascular disease (4) | Chronic lung disease (18) Malignancy (7) Chronic kidney disease (4) Autoimmune disease (2) | 72–18              | NA                                      | NA                        | ARDS (192) Sepsis (179) AKI (29) DIC (21) Shock (46) Acute liver injury (13) Mechanical ventilation (119) CRRT (3) ECMO (1) | Death (113) Recovered (161) |
| Authors         | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value | LVEDV – EF (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|-----------------|--------------------------|-----------------------------|---------------------------|---------|-------------------------------------|-----------------------------|-------------------|-----------------------------------------------|---------------------------------------------|------------------------------------------|-------------------------------|---------------------------------------------|
| Du et al. [22]  | 65.8 ± 14.2°             | NA                          | NA                        | 62/23   | Hypertension (32)                  | Diabetes (19)              | Chronic liver disease (5) | 38                             | NA                                          | NA                                      | Respiratory failure (80)                       | Death (51)                           |
|                 |                          |                             |                           |         | Coronary heart disease (10)        | Cerebrovascular diseases (7) | Chronic kidney disease (3) |                   | NA                                          | NT-proBNP 268.4 (175.3–689.1)§         | NA                                      | Acute coagulopathy (42)                  | Death (12-31)                        |
| Guo et al. [25] | 58.5 (14.66)°            | 53.53 (13.22)°              | 34 (654)°                 | 91/96   | Smoking (18)                        | Hypertension (61)          | Chronic kidney disease (6) | 135–52                         | NA                                          | ARDS (46)                               | Death (12-31)                        |
|                 |                          |                             |                           |         | Coronary heart disease (21)        | Cardiomyopathy (8)         | Chronic kidney disease (6) |                   | NA                                          | ARDS (12)                               | Death (6)                              | Discharge (28)                        |
| Huang et al. [27]| 49 (41–61)°              | 49 (41–61)°                 | 49 (41–57.5)°             | 30/11   | Smoke (3)                           | Hypertension (6)           | COPD (1)                         | 4-1                              | TnI > 28 pg/ml                              | NA                                      | Respiratory failure (71)                       | Death (68)                          |
|                 |                          |                             |                           |         | Diabetes (8)                        | Cardiovascular disease (6) | Malignancy (1)                  |                   | NA                                          | ARDS (62)                               | Discharged (82)                       |                               |
| Ruan et al. [39]| NA                       | 67 (15–81)°                 | 50 (44–81)°               | 102/48  | Hypertension (52)                   | Cardiovascular disease (13) | COPD (3)                         | 27                             | NA                                          | NA                                      | Respiratory failure (71)                       | Death (68)                          |
|                 |                          |                             |                           |         | Diabetes (25)                       | Cerebrovascular disease (12) | Chronic kidney disease (2)     |                   | NA                                          | ARDS (62)                               | Invasive mechanical ventilation (2)         |                               |
| Shao et al. [42]| 73.5 (29–66)°            | NA                          | NA                        | 13/5    | Hypertension (10)                   | Diabetes (4)               | Renal disease (3)                | 10                             | NA                                          | NA                                      | ARDS (17)                               | Death (10)                           |
|                 |                          |                             |                           |         | Cerebrovascular disease (5)         |                              | Malignancy (2)                  |                   | NA                                          | Invasive mechanical ventilation (11)      |                               |                               |

*Table 2: Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction” (Continued)*
Table 2 Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction” (Continued)

| Authors            | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value | LVEDV – EF (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------|--------------------------|----------------------------|--------------------------|---------|------------------------------------|----------------------------|-------------------|------------------------------------------------|--------------------------------------------|------------------------------------------|-------------------------------|----------------------------------|
| Kunal et al. [32]  | 51.2 ± 17.7              | 60.9 ± 15.1                | 47.9 ± 17.4              | 70/38   | Hypertension (41)                  | COPD (6)                | NA               | 28–80                                          | TnT 0.66 ± 128 mcg/L                  | NA                                      |                               | AKI (7) Shock (6) ECMO (1) Gastrointestinal bleeding (1) Perforation of the intestine (1) Co-infection (5) Death (16-14) |
| Shi et al. [43]    | 64 (21–95)§              | 74 (34–95)§                | 60 (21–90)§              | 205/211 | Hypertension (127)                 | chronic kidney disease (14) | COPD (12) Malignancy (9) Hepatitis B infection (4) | NA                                           | Hs TnI 0.19 (0.08–1.12) mcg/L§ NT-proBNP 1689 (698–3327) pg/ml§ | NA                                      | Noninvasive ventilation (51) Invasive mechanical ventilation (32) CRRT (2) ARDS (97) AKI (8) Death (42-15) Discharge (2-38) Recovered (38-281) |
| Shi et al. [44]    | 63 (50–72)§              | 73 (66–80)§                | 57 (43–70)§              | 322/349 | Hypertension (199)                 | Chronic renal disease (28) COPD (23) Cancer (23) | Severe and critical diseases are defined by the presence of any of RR > 30 acts/min oxygen saturation ≤ 93%; PaO2/FiO2 ratio < 300 mmHg; respiratory failure requiring mechanical ventilation; shock; respiratory failure with other organ failure requiring ICU management | 106                                          | TnI 0.159 (0.075–0.695) ng/ml§ NT-proBNP 1346 (474–3018) pg/ml§ | NA                                      | Invasive mechanical ventilation (36) ECMO (2) CRRT (4) Death (62) Survivors (609) |
| Szekely et al. [47]| 66.1 ± 17.3              | 65.9 ± 20°                 | 69.8 ± 16°               | 63/37   | Hypertension (57)                  | Chronic renal disease (10) Diabetes (29) Obesity (29) Asthma (7) Malignancy (5) | Acuity score | Troponin level above the 99th percentile was reported | Tn I 111 (5–39) ng/L § BNP 43 (18–144) pg/L§ | EF 58.2 ± 4° NA | NA                            | NA                              |
## Table 2 Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction” (Continued)

### Acute cardiac injury

| Authors | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value* | LVEDV – EF (n° pts or cases-controls)* | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|---------|--------------------------|-----------------------------|---------------------------|---------|-----------------------------------|-----------------------------|-------------------|---------------------------------------------|---------------------------------------------|--------------------------------|---------------------------------|---------------------------------|
| Tavazzi et al. [48] | 69* | NA | NA | 1/0 | NA | NA | NA | in 20% of the patients | 1 | NA | LVEDV 56 mm* | Bilateral interstitial pneumonia (1) Mechanical ventilation (1) IABP (1) ECMO (1) Septic shock (1) | Death (1) |
| Wan et al. [50] | 47 (36–55)§ | 44 (33–49)§ | 56 (52–73)§ | 72/63 | Current smoking (9) Diabetes (12) Hypertension (13) | Malignancy (4) Pulmonary disease (1) Chronic liver disease (2) | The mild group had mild symptoms and no pneumonia; the normal group had fever, respiratory symptoms, and pneumonia; the severe group had respiratory distress, RR ≥ 3 acts/min at rest, mean oxygen saturation ≤ 93%, and P/F ≤ 300 mmHg; the critical group had respiratory failure with mechanical ventilation, shock, and other failures, requiring ICU treatment | 8-2 | NA | NA | ARDS (21) AKI (5) Secondary infection (7) Shock (1) CRRT (5) Invasive mechanical ventilation (1) | Death (0-1) Discharge (10-5) Hospitalization (85-35) |
| Xiong et al. [52] | 58.5 (47–69)§ | 56 (37–64)§ | 64 (53–76)§ | 80/63 | Diabetes (19) Hypertension (45) Coronary Heart Disease (17) Cardiovascular disease (8) | COPD (1) Malignancy (4) Chronic liver disease (2) | Moderate cases mild respiratory symptoms with pneumonia Severe cases: dyspnea, RR ≥ 30/min, blood oxygen saturation ≤ 93%, PaO₂/FIO₂ ratio ≤ 300 mmHg, and/or pulmonary inflammation progressing > 50% within 24 to 48 h. Critical cases: respiratory failure, shock, and/or multiple organ dysfunction | 4-19 | TnT > 0.02 ng/ml* NT-proBNP 71.5 (27–363.5)§ pg/ml | NA | Shock (16) ARDS (20) Liver dysfunction (15) AKI (3) Invasive mechanical ventilation (10) ECMO (8) | Discharge (61-48) Death (0-7) |
| Yang et al. | 59.7 | 51.9 (12.9)§ | 64.6 | 14/6 | Chronic cardiac | Chronic | Admission to ICU requiring | 3-9 | Tnl > 28 pg/ml | NA | ARDS (35) | Death (32) |
Table 2 Characteristics and outcomes of retrieved trials for the outcome "Acute cardiac injury" and "Acute myocardial infarction" (Continued)

### Acute cardiac injury

| Authors           | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value* | LVEDV – EF (n° pts or cases-controls)* | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|-------------------|--------------------------|-----------------------------|---------------------------|---------|-------------------------------------|----------------------------|------------------|-----------------------------------------------|---------------------------------------------|-------------------------------------------|----------------------------------------|---------------------------------|
| Yu et al. [54]    | 64 (57–70)§              | NA                          | NA                        | 139/87  | Hypertension (96) Coronary heart disease (22) Myocardial infarction (6) Congestive heart failure (4) Diabetes (47) Cerebrovascular disease (15) | Chronic pulmonary disease (15) Chronic heart disease (15) | RR > 40 acts/min, PaO₂ < 60 mmHg, SpO₂ < 90% with oxygen support of ≥ 27 L/min for at least 30 min, PaCO₂ > 50 mmHg, hemodynamic instability, use of vasopressors, GCS ≤ 12, CRRT | 61 TnI > 0.3 ng/mL NA | ARDS (161) Shock (36) AHI (37) Bacterial or fungal infection (49) Gastrointestinal hemorrhage (7) | Discharge (20) |
| Zhang et al. [56] | 55 (39–66.5)§            | 62 (52–74)§                 | 51 (36–64.3)§            | 108/113 | Hypertension (54) Diabetes (22) Cardiovascular disease (22) Cerebrovascular disease (15) | COPD (6) Chronic kidney disease (6) Chronic liver disease (7) Malignancy (9) | Admission in ICU | 16-1 NA | NA | ARDS (48) Shock (15) AHI (10) CRRT (5) Mechanical ventilation (16) ECMO (10) | Death (12-0) Discharge (7-35) Hospitalization (36-131) |
| Zhao et al. [57]  | 46§ 50.5§ 42§            | 49/42                       | COPD (1) Autoimmune disease (1) Kidney disease (1) Malignancy (3) | 8-6     | NA | NA | Pneumonia (91) Digestive tract disease (14) Liver disease (18) Renal disease (5) Coagulopathy (19) Mechanical ventilation (5) CRRT (3) | Death (2-0) Discharge (14-2) Hospitalization (26-49) |

* COVID-19 severity: mechanical ventilation or FiO2 ≥ 60%
### Table 2: Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction” (Continued)

#### Acute cardiac injury

| Authors | Age (years) all patients | Age (years) treatment group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value* | LVEDV – EF (n° pts or cases-controls)* | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|---------|--------------------------|-----------------------------|---------|------------------------------------|-----------------------------|------------------|-----------------------------------------------|---------------------------------------------|------------------------------------------|---------------------------------------|-----------------------------------|
| Zhou et al. [58] | 56 (46–67)§ | 69 (63–76)§ | 119/72 | Hypertension (58) | COPD (6) | NA | 32-1 | Tnl > 28 pg/ml | NA | Sepsis (112) | Death (54) |
| Barton et al. [14] | 77/42+ | 77 | 42 | Hypertension (2) | Chronic kidney disease (1) | NA | STEMI (8) | TnI 6.3 (5.3–72) ng/ml§ | NA | ARDS (1) | Death (2) |

#### Acute myocardial infarction

| Authors | Age (years) all patients | Age (years) treatment group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | EKG (n° pts) | Coronarography/PCI (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP value* | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|---------|--------------------------|-----------------------------|---------|------------------------------------|-----------------------------|------------------|------------|-----------------------------------------------|---------------------------------------------|---------------------------------------|-----------------------------------|
| Bangalore et al. [13] | 63 (54–73)§ | 60 (56-73)§ | 66 (54-73)§ | Hypertension (11) | Chronic kidney disease (1) | NA | STEMI (8) | TnI 6.3 (5.3–72) ng/ml§ | NA | ARDS (1) | Death (4-9) |
| Barton et al. [14] | 77/42+ | 77 | 42 | Hypertension (2) | Oncocytoma (1) | NA | STEMI (1) | 1/1 | NA | Bilateral | Discharge (1) |
Table 2 Characteristics and outcomes of retrieved trials for the outcome “Acute cardiac injury” and “Acute myocardial infarction” (Continued)

| Authors            | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Acute cardiac injury (n° pts or cases-controls) | Troponin T or I value—BNP or NT-proBNP valuea | LVEDV – EF (n° pts or cases-controls)b | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------|--------------------------|-----------------------------|---------------------------|---------|-------------------------------------|-----------------------------|---------------------|-----------------------------------------------|------------------------------------------|---------------------------------------|--------------------------------------|-------------------------------------|
| Erquicia et al. [20] | 64 (53–73)6              | 60 (51–69)§                 | 64 (53–73)§              | 844/365 | Hypertension (445)                  | NA                          | NA                  | NA                                            | NA                                      | NA                                    | NA                                   | pneumonia (1)                       |
| Dweck et al. [24]   | 62 (52–71)§              | 64 (53–73)§                 | 60 (51–69)§              | NA      | Diabetes (233)                      | Ischemic heart disease (167) | Heart failure (113) | VAricular disease (80)                         | NA                                      | NA                                    | NA                                   | NA                                  |
| Kim HN et al. [30]  | 60*                      | NA                          | NA                        | 1/0     | Hypertension (1)                    | Diabetes (1)                | Dyslipidemia (1)    | NA                                            | NA                                      | NA                                    | NA                                   | STEMI (1)                           |
| Kunal et al. [32]   | 51.2 ± 17.7*             | 609 ± 15.1*                 | 47.9 ± 17.4*             | 70/38   | Hypertension (41)                   | Diabetes (35)               | Cardiovascular disease (14) | Dyslipidemia (6) Heart failure (1)               | STEMI (3) NSTEMI (1)                      | NA                                    | NA                                   | Death (16-14)                        |
| Stefanini et al. [46] | 68 ± 11*                 | NA                          | NA                        | 20/8    | Hypertension (20)                   | Diabetes (9) Previous myocardial infarction (3) | NA | STEMI (25) New LBBB (3)                        | 28/17                                    | NA                                    | NA                                   | Death (11) Discharge (16) ICU (1)       |

Data are presented as real number*, percentage*, mean ± SD, or median and (IQR)§

M male, F female, pts patients, TnT troponin T, TnI troponin I, BNP brain natriuretic peptide, NT-proBNP N-terminal pro-brain natriuretic peptide, EF ejection fraction, LVEDV left ventricular end-diastolic volume, NA not applicable, ECMO extra-corporeal membrane oxygenation, CRRT continuous renal replacement therapy, ARDS acute respiratory distress syndrome, RR respiratory rate, SpO2 peripheral oxygen saturation, P/F PaO2/FiO2, PaO2 partial pressure of oxygen in arterial blood, FiO2 oxygen inspired fraction, PaCO2 pressure of arterial carbon dioxide, AKI acute kidney injury, COPD chronic obstructive pulmonary disease, ICU intensive care unit, NIV noninvasive ventilation, HIV human immunodeficiency virus, IABP intra-aortic balloon pump, PCI percutaneous coronary intervention, EKG electrocardiogram, STEMI ST-elevation myocardial infarction, DIC disseminated intravascular coagulation, LBBB left bundle branch block

As reported in studies, not better specified; *referred to patient with complication in exam
### Table 3 Characteristics and outcomes of retrieved trials for outcome “Takotsubo syndrome”

| Authors          | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex (M/F) | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Type of CMP (n° pts or cases-controls) | Troponin T or I values – BNP or NT-proBNP values \( ^{n} \) | EF value (n° pts)\( ^{\pi} \) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|------------------|-------------------------|-----------------------------|---------------------------|-----------|-------------------------------------|-----------------------------|------------------|--------------------------------------|-------------------------------------------|----------------|--------------------------------------|---------------------------------|
| Dabbagh et al. [18] | 63\( ^{+} \)           | NA                          | NA                        | 0/1       | Dilated cardiomyopathy (1)         | NA                           | NA               | Takotsubo syndrome (1)               | Tn I 2410 ng/L\( ^{\pi} \)               | 40%           | NA                                   | Discharge (1)                      |
| Dweck et al. [24]  | 62 (52–71)\( ^{\delta} \) | 64 (53–73)\( ^{\delta} \)   | 60 (51–69)\( ^{\delta} \) | 84/365    | Hypertension (445) Diabeties (233) | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | NA               | Takotsubo syndrome (19)               | NA                                          | NA            | NA                                   | NA                               |
| Meyer et al. [34]  | 83\( ^{+} \)           | NA                          | NA                        | 0/1       | Hypertension (1)                  | NA                           | NA               | Takotsubo syndrome (1)               | TnT 1142 ng/L\( ^{+} \)                 | NA            | Pneumonia (1)                        | Discharge (1)                      |
| Sala et al. [40]   | 43\( ^{+} \)           | NA                          | NA                        | 0/1       | NA                                 | NA                           | NA               | Inverted Takotsubo syndrome (1)      | TnI 64 pg/ml\( ^{+} \) NT-proBNP 512 pg/mL\( ^{+} \) | 43%          | NA                                   | NA                               |
| Solano-Lopez et al. [45] | 50\( ^{+} \)     | NA                          | NA                        | 1/0       | Mediastinal tumor (1)              | NA                           | NA               | Inverted Takotsubo syndrome (1)      | TnI 790 pg/ml\( ^{+} \) NT-proBNP 512 pg/mL\( ^{+} \) | NA            | Pneumonia (1)                        | Discharge (1)                      |
| Stöbe et al. [46]  | 64 ± 19.1\( ^{+} \)    | 71 ± 15.2\( ^{+} \)         | 41 ± 11.8\( ^{+} \)       | 14/4      | Hypertension (13) Paroxysmal atrial fibrillation (4) Coronary artery disease (2) Dyslipidemia (4) Diabetes (5) Stroke (3) | Chronic kidney disease (7) COPD (1) Severe symptoms: mechanical ventilation needed | Inverted Takotsubo (7/1) | Inverted Takotsubo (7/1) | TnI 36 ± 23 pg/ml\( ^{+} \) NT-proBNP 1724 ± 1058 pg/ml\( ^{+} \) | 62 ± 65%\( ^{+} \) | Mechanical ventilation (14) | NA                               |

Data are presented as real number\( ^{+} \), percentage\( ^{+} \), mean ± SD, or median and (IQR)\( ^{\delta} \)

\( ^{M} \) male, \( ^{F} \) female, pts patients, \( ^{CMP} \) cardiomyopathy, \( ^{TnT} \) troponin T, \( ^{Tr} \) troponin I, \( ^{BNP} \) brain natriuretic peptide, \( ^{NT-proBNP} \) N-terminal pro-brain natriuretic peptide, \( ^{EF} \) ejection fraction, \( ^{LVEDV} \) left ventricular end-diastolic volume, \( ^{NA} \) not applicable, \( ^{ICU} \) intensive care unit, \( ^{COPD} \) chronic obstructive pulmonary disease

\( ^{\delta} \) As reported in studies, not better specified; \( ^{\pi} \) referred to patient with complication in exam
### Table 4 Characteristics and outcomes of retrieved trials for the outcome “Myocarditis”

| Authors          | Age (years) | Age (years) | Age (years) | Sex | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | N° pts of cases-controls with myocarditis | Troponin T or I value -BNP or NT-proBNP value | LVEDV - EF (n° pts or cases-controls) | Inotropes and corticosteroids | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|------------------|-------------|-------------|-------------|-----|-------------------------------------|-----------------------------|-------------------|------------------------------------------|---------------------------------------------|-----------------------------------------|-----------------------------------|-----------------------------------|------------------------------------------|------------------------------------------|
| Deng et al. [19] | 65 (49–70.8) | 68 (57–77)² | 56 (39–67)³ | 57/ 55 | Hypertension (96), Diabetes (19), Coronary heart disease (15), Atrial fibrillation (4) | COPD (4) | Severe patients if: Respiratory distress and RR > 30 acts/min or SpO2 < 93% or P/F < 300. Critical patients if: Respiratory failure with mechanical ventilation or shock or multi-organ failure that require hospitalization in UTI | 13/1 | TnI > 0.12 ng/ml⁻¹ | NA | NA | Mechanical ventilation (28) | Death (14) |
| Dweck et al. [24] | 62 (52–71)² | 64 (53–73)³ | 60 (51–69)³ | 844/ 365 | Hypertension (445), Diabetes (233), Ischemic heart disease (167), Heart failure (113), Valvular disease (80) | NA | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | 35 | NA | Low EF (21) | NA | NA | NA | NA |
| Doyen et al. [21] | 69⁺ | NA | NA | 1/0 | Hypertension (1) | NA | NA | 1 | TnI 900.2 ng/L⁺ | Normal EF | Hydrocortisone | Mechanical ventilation (1) | Discharge (1) |
| Hu et al. [26] | 37⁺ | NA | NA | 1/0 | NA | NA | NA | 1 | TnI > 10,000 ng/L⁻¹ | BNP > 21,025 ng/L⁻¹ | NT-proBNP 518 mm⁻¹ | EF 27%⁺ | Dobutamine | ARDS (1) | Death (1) |
| Hussain et al. [28] | 51⁺ | NA | NA | 1/0 | Hypertension (1) | NA | NA | 1 | TnI 0.29 ng/ml⁻¹ | BNP 1,287 pg/ml⁻¹ | NT-proBNP 5647 pg/ml⁻¹ | EF 35%⁺ | Dobutamine | Methylprednisolone | Not reported | Hospitalized (1) |
| Inciardi et al. [29] | 52⁺ | NA | NA | 0/1 | NA | NA | NA | 1 | TnI 0.24 ng/ml⁻¹ | NT-proBNP 19.29 pg/ml⁻¹ | NT-proBNP 29 ng/ml⁻¹ | EF 50–55% | Dobutamine | Methylprednisolone | NA | NA | Sepsis (25) | ARDS (12) | AKI (8) | Diabetic ketoacidosis (3) | Intracranial hemorrhage (1) | Death (1) | Recovery (2) |
| Kim IC et al. [31] | 21⁺ | NA | NA | 0/1 | NA | NA | NA | 1 | TnI 1,26 ng/ml⁻¹ | NT-proBNP 19.29 pg/ml⁻¹ | Severe dysfunction EF | NA | NA | PAE (25) | ARDS (12) | AKI (8) | Diabetic ketoacidosis (3) | Intracranial hemorrhage (1) | Death (1) | Recovery (2) |
| Kunal et al. [32] | 51.2 ± 17.7⁺ | 60.9 ± 15.1⁺ | 47.9 ± 17.4⁺ | 70/ 38 | Hypertension (41), Diabetes (5), Cardiovascular disease (14), Dyslipidemia (6), Heart failure (1) | COPD (6) | NA | 3 | TnI 29 ng/ml⁻¹ | NT-proBNP 456 pg/ml⁻¹ | NT-proBNP 29 ng/ml⁻¹ | EF 50–55% | Methylprednisolone | Pneumonia (1) | Discharge (1) |
| Mannoneu et al. [35] | 43⁺ | NA | NA | 1/0 | NA | NA | NA | 1 | TnI 1033 ng/ml⁻¹ | NT-proBNP 56 pg/ml⁻¹ | NT-proBNP 29 ng/ml⁻¹ | EF 50–55% | Methylprednisolone | Pneumonia (1) | Discharge (1) |
| Pascarelli [36] | 19⁺ | NA | NA | 1/0 | Autistic | NA | NA | 1 | TnI 1033 ng/ml⁻¹ | NT-proBNP 56 pg/ml⁻¹ | NT-proBNP 29 ng/ml⁻¹ | EF 50–55% | Methylprednisolone | Pneumonia (1) | Discharge (1) |
### Table 4: Characteristics and outcomes of retrieved trials for the outcome "Myocarditis" (Continued)

| Authors            | Age (years) | All patients | Age (years) treatment group | Age (years) control group | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | N° pts or cases-controls with myocarditis | Troponin T or I value -BNP or NT-proBNP value | LVEDV – EF (n° pts or cases-controls) | Inotropes and corticosteroids | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------|-------------|--------------|-----------------------------|---------------------------|---------|-------------------------------------|-----------------------------|-------------------|------------------------------------------|---------------------------------------------|-------------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|
| et al. [36]        |             |              |                             |                           |         | spectrum disorder (1)               |                             |                   | NT-proBNP 47,650 ng/L*                   | mm* EF 15–20%*                              | Dexamethasone, interstitial pneumonia (1) | Mechanical ventilation (1)          | (1)                               |
| Paul et al. [37]  | 35+         | NA           | NA                          | 1/0                       | NA      | NA                                  | NA                          |                   | TnI 2885 ng/L                            | Normal EF                                  | NA                                | NA                                | Discharge (1)                           | (1)                               |
| Zeng et al. [55]  | 63+         | NA           | NA                          | 1/0                       | NA      | Smoke (1)                           | Allergic cough (1)         |                   | TnI 11.37 g/L NT-proBNP 22,600 pg/mL* | LVEDV 61 mm* EF 32%*                      | Methylprednisolone Immunoglobulins ARDS (1) CORT (1) ECMO (1) | Septic shock (1)                             | Death (1)                             |

Data are presented as real number*, percentage*, mean ± SD, or median and (IQR)*

M male, F female, pts patients, TnT troponin T, TnI troponin I, BNP brain natriuretic peptide, NT-proBNP N-terminal pro-brain natriuretic peptide, EF ejection fraction, LVEDV left ventricular end-diastolic volume, COPD chronic obstructive pulmonary disease, RR respiratory rate, SpO2 peripheral oxygen saturation, P/F PaO2/FiO2, PaO2 partial pressure of oxygen in arterial blood, FiO2 oxygen inspired fraction, NA not applicable, ECMO extra-corporeal membrane oxygenation, ARDS acute respiratory distress syndrome, AKI acute kidney injury, CORT continuous renal replacement therapy

*As reported in studies, not better specified; °referred to patient with complication in exam
### Table 5: Characteristics and outcomes of retrieved trials for the outcome “Pericardial Effusion”

| Authors            | Age (years) | Age (years) | Age (years) | Sex M/F | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Volume (n° pts or cases-controls) | Cardiac tamponade (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------|-------------|-------------|-------------|---------|-------------------------------------|-----------------------------|--------------------|-----------------------------------|------------------------------------------|----------------------------------------|---------------------------------------|
| Chen et al. [16]   | 57.6 (44.9–70.3)§ | 56.1 ± 13.5° | 61.7 ± 9.6° | 36/18   | Hypertension (16) Diabetes (25) Coronary heart disease (6) | NA                          | Severe condition: Respiratory distress, RR > 30 acts/min or SpO₂ < 93% at rest or P/F < 300 Critical condition if: Mechanical ventilation or shock or failure of other organs that requires monitoring and treatment in ICU | Not reported (1–5) | 0 | AKI (18) | NA |
| Dabbagh et al. [18] | 63+ NA NA 0/1 | Dilated cardiomyopathy (1) Chronic heart failure (1) | NA | NA | NA | 800 ml* (1) | 1 | NA | Discharge (1) |
| Deng et al. [19]   | 65 (49–708)§ | 56 (39–67)§ | 68 (57–77)§ | 57/55   | Hypertension (36) Diabetes (19) Coronary heart disease (15) Atrial fibrillation (4) | COPD (4) | Severe patients if: Respiratory distress and RR> 30 acts/min or SpO₂ < 93% or P/F < 300 Critical patients if: Respiratory failure with ventilation mechanical or shock or multi-organ failure requiring hospitalization in ICU | 6.2 ± 1.1 mm° (3–19) | 0 | Mechanical ventilation (28) ECMO (3) | Death (14) Discharge (37) |
| Dweck et al. [24]  | 62 (52–71)§ | 64 (53–73)§ | 60 (51–69)§ | 844/365 | Hypertension (445) Diabetes (233) Ischemic heart disease (167) Heart failure (113) Valvular disease (80) | NA | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | Not reported (11) | 11 | NA | NA |
| Kunal et al. [32]  | 51.2 ± 17.7° | 60.9 ± 15.1° | 47.9 ± 17.4° | 70/38   | Hypertension (41) Diabetes (35) Cardiovascular disease (14) Dyslipidemia (6) Heart failure (1) | COPD (6) | NA | Not reported (2) | Sepsis (25) ARDS (12) AKI (8) Diabetic ketoacidosis (3) Intracranial hemorrhage (1) | NA | NA |

Data are presented as real number*, percentage*, mean ± SD, or median and (IQR)*. M male, F female, pts patients, RR respiratory rate, SpO₂ peripheral oxygen saturation, P/F PaO₂/FiO₂ PaO₂ partial pressure of oxygen in arterial blood, FiO₂ oxygen inspired fraction, AKI acute kidney injury, NA not applicable, ECMO extra-corporeal membrane oxygenation, ICU intensive care unit, ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease

*As reported in studies, not better specified; °referred to patient with complication in exam
COVID-19 was the main aim of 15 articles [12, 15, 17, 22, 23, 27, 39, 42, 50, 52–54, 56–58]. The severity of respiratory involvement was defined as:

- Need for mechanical ventilation or severe acute hypoxic respiratory failure [11, 63]
- Respiratory rate (>30 breaths/minute), oxygen saturation <93%, PaO₂/FiO₂ <300, or respiratory failure/shock/multi-organ failure [16, 44, 50, 52]
- Respiratory distress for a respiratory rate >40 breath/minute, peripheral saturation <90% and PaO₂ <60 mmHg/with 7 l/min, PaCO₂ >50 mmHg, hemodynamic instability or vasopressor therapy, GCS<12, the need of CRRT [54]
- Clear reference to national and international guidelines [17, 19, 27, 42, 51, 53, 56]

Primary outcome: cardiac complications and risk factors

**Acute cardiac injury, acute myocardial infarction, cardiogenic shock, heart failure**

Acute cardiac injury was evaluated in 20 articles (as shown in Table 2): 17 retrospectives [15–17, 22, 25, 27, 32, 39, 42–44, 50, 52, 53, 56, 57, 64], two prospective observational studies [47, 54], and one international survey [24]. Heart failure and cardiogenic shock were reported in 10 articles [12, 16, 17, 22, 32, 44, 47, 48, 52, 54]. Acute cardiac injury (ACI) was defined as an increased in cardiac biomarker level [16, 25, 32, 43, 44, 47, 49, 52–54, 57] and/or new abnormalities in ECG/echocardiographic evaluations [17, 22, 27, 58]. Six of the aforementioned studies analyzed cardiac complications in patients with COVID-19 as first objective [16, 32, 43, 44, 48, 52]. Myocardial infarction was evaluated in seven of the papers retrieved (as shown in Table 2): one international survey [24], two retrospective [32, 46], one autopsy report [14], and three case reports [13, 20, 30]. Six out of seven of the aforementioned studies analyzed cardiac complications in patients with COVID-19 as first objective [13, 20, 24, 30, 32, 46].

Characteristics and outcomes of retrieved articles for acute cardiac injury and acute myocardial infarction are listed in Table 2.

In the retrospective study of Kunal et al., the authors enrolled 108 patients with COVID-19 [32] and ACI was defined as serum levels of troponin T above the 99th percentile upper reference limit. The authors found that ACI was the most common CV complication (25.9% of the patients). Heart failure, cardiogenic shock, and acute coronary syndrome were observed in 3.7% of the patients. Patients with ACI were significantly older and had a greater frequency of hypertension, diabetes, and cardiovascular disease in their medical history (P = 0.001). The authors also found a statistically significant difference between non-survivor and survivor in patients with acute cardiac injury (P = 0.01). No correlation was observed regarding the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and acute cardiac injury. Univariate logistic regression analysis found that acute cardiac injury was a predictor of mortality (OR: 6.28; 95% CI: 2.44–16.17; P < 0.0001). Multivariate logistic regression analysis found that acute cardiac injury was the independent predictor of mortality (OR: 11.3; 95% CI: 2.31–55.54; P = 0.003). Likewise, in the retrospective study of Guo et al., the authors found cardiac injury in 27.8% of the COVID-19 patients [25]. Cardiac injury was defined as serum levels of troponin T above the 99th percentile upper reference limit. Patients with cardiac injury had a significantly higher rate of hypertension (P < 0.001), coronary artery disease (P < 0.001), cardiomyopathy (P < 0.001), diabetes (P < 0.001), chronic obstructive pulmonary disease (P = 0.001), and history of ACEI/ARB use (P = 0.002). Patients with cardiac injury were more likely to develop complications during hospital stay (i.e., malignant arrhythmia, acute respiratory distress syndrome, acute coagulopathy acute kidney injury). The mortality rate was 37.50% for patients with cardiac injury and 69.44% for patients with cardiac injury and cardiovascular disease in their medical history. Shi et al., in a retrospective study of 416 patients, evaluated the incidence of cardiac complications and the association between cardiac injury and mortality [43]. Cardiac injury was defined as an increase of troponin above the 99th percentile upper reference limit. A diagnosis of acute cardiac injury was made in 82 patients (19.7%). Patients with ACI were older and with comorbidities (i.e., hypertension, coronary heart disease, cerebrovascular disease, chronic heart failure) in comparison to COVID patients without cardiac injury (P < 0.001). Troponin and pro-BNP levels were statistically significantly higher in patients with cardiac injury (P < 0.001). Even more, in the group of cardiac injury patients, the authors found a higher incidence of invasive mechanical ventilation, use of antibiotics, glucocorticoids, immunoglobulin, acute kidney injury, electrolytes alterations, coagulation disorders, and ARDS. The mortality rate was also higher in this group of patients (P < 0.001). Similar findings can be observed in the single-center retrospective observational study by Xiong et al., evaluating the cardiovascular implication in COVID-19 patients [52]. Cardiac injury was defined as an increase in serum troponin T above the upper limit of reference (>0.02 ng/mL), whereas acute heart failure was defined as the presence of typical symptoms in addition to signs of structural and/or functional cardiac abnormalities. They found that 19.8% had acute cardiac injury and 18.1% had acute heart failure. Acute cardiac injury was the most common complication among COVID-19 patients. The prevalence of cardiac complications was
Table 6: Characteristics and outcomes of retrieved trials for the outcome “Arrhythmias”

| Authors          | Age (years) all patients | Age (years) treatment group | Sex M/F | Age (years) control group | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity                  | Type of arrhythmia (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|------------------|--------------------------|-----------------------------|---------|---------------------------|--------------------------------------|-------------------------------|----------------------------------|------------------------------------------|----------------------------------------|------------------------------------|
| Amaratunga et al. [11] | 55/60/78/74² | NA                          | NA      | 2/2                       | Coronary heart disease (2)            | Hypothyroidism (2)            | Severe acute respiratory failure hypoxic, resulting intubation, and mechanical ventilation | Sinus Bradycardia (4)                   | NA                                    | NA                                 |
| Cao et al. [15]   | 54 (37–67)³          | 66 (54–76)³                 | 93/10   | 53/49                     | Hypertension (28)                     | Diabetes (11)                 | Patients subjected to mechanical ventilation, ECMO, and CRRT | Unspecified (7–11)                      | Shock (10)                           | Death (6–11)                        |
| Chen et al. [16]  | 57.6 (44.9–70.3)      | 56.1 ± 13.5 ⁶               | 36/18   | NA                       | Hypertension (16)                     | Diabetes (25)                | Severe condition if: Respiratory distress, RR > 30 acts/min or SpO₂ < 93% rest or P/F < 300 | Sinus tachycardia (38)                  | AKI (18)                             | NA                                 |
| Deng et al. [19]  | 65 (49–70.8)⁴        | 68 (57–77)⁴                 | 57/55   | NA                       | Hypertension (36)                     | Diabetes (19)                | Severe patients if: Respiratory distress and RR > 30 acts/min or SpO₂ < 93% or P/F < 300 | Tachycardia (11–22)                    | Mechanical ventilation (28)            | Death (14)                          |
| Du et al. [22]    | 65.8 ± 14.2 ²        | NA                          | NA      | 62/23                     | Hypertension (32)                     | Diabetes (19)                | On the recommendations by the National Institute for Viral Disease Control and Prevention, China (8th edition) | Unspecified (51)                       | Respiratory failure (80)              | Death (51)                          |
| Dweck et al. [24] | 62 (52–71)⁵          | 64 (53–73)⁵                 | 24/44   | NA                       | Hypertension (445)                    | Diabetes (233)               | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | Ventricular tachycardia (33–5)          | NA                                    | NA                                 |
| Guo et al. [25]   | 58.5 (14.66)⁷        | 53.53 (13.22)²              | 91/96   | Smoking (18)              | Hypertension (13)                     | COPD (4)                      | Ventricular arrhythmia (33–5) | NA                                      | NA                                    | Ventricular tachycardia (11)          | ARDS (46)                           |

Note: M/F: Male/Female; COVID-19 severity: Severe acute respiratory failure hypoxic, resulting intubation, and mechanical ventilation; Other no cardiac complications: ARDS (Acute respiratory distress syndrome), AKI (Acute kidney injury), Sepsis (Severe sepsis), Shock (Sepsis with septic shock), Death (Any cause of death).
| Authors            | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex M/F* | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Type of arrhythmia (n° pts or cases-controls) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
|--------------------|--------------------------|-----------------------------|---------------------------|----------|--------------------------------------|-----------------------------|-------------------|-----------------------------------------------|----------------------------------------|-------------------------------|
| Kunui et al. [32]  | 51.2 ± 17.7^             | 609 ± 15.1^                 | 47.9 ± 17.4^              | 70/38    | Hypertension (41)                    | COPD (6)                    | NA                | Ventricular tachycardia (1)                  | Sepsis (25)                            | NA                            |
| Peigh et al. [38]  | 70–81+                   | NA                          | NA                        | 1/1      | Ascending aorta aneurism (1)        | Obstructive sleep apnea (1) | Mechanical ventilation | Sinus bradycardia (2) | Respiratory failure and mechanical ventilation (2) | NA                          |
| Seecheran et al. [41] | 46^                     | NA                          | NA                        | 1/0      | NA                                   | NA                          | NA                | Atial flutter (1)                              | NA                          | Discharge (1)                       |
| Villanueva et al. [49] | 68^                     | NA                          | NA                        | 1/0      | Atrial flutter (1)                   | Chronic kidney disease stage 3 (1) | NA                | Atrial flutter (1)                              | Interstitial pneumonia (1)               | NA                            |
| Yu et al. [54]     | 64 (57–70)^§             | NA                          | NA                        | 139/ 87  | Hypertension (96)                    | Chronic pulmonary disease (15) | RR > 40 acts/min, PaO2 < 60 mmHg, SpO2 < 90% with oxygen support of ≥7 L/min for at least 30 min, PaCO2 > 50 mmHg, hemodynamic instability, use of vasopressors, GCS ≤ 12, CRRT | Atrial fibrillation (18) | ARDS (16) | Death (9) Discharge from ICU (13) Bacterial or fungal infection (49) Gastrointestinal hemorrhage (7) |
| Zhang et al. [56]  | 55 (39–66.5)^§           | 62 (52–74)^§                | 51 (36–64.3)^§            | 108/113  | Hypertension (54)                    | COPD (6)                    | Admission in ICU | Unspecified (2-2) | ARDS (48) Shock (13) AKI (10) CRRT (6) Mechanical ventilation (16) ECMO (10) | Death (12-0) Discharge (7-35) Hospitalization (36-131) |

Data are presented as real number^†, percentage^‡, mean ± SD, or median and (IQR)^§

M male, F female, pts patients, NA not applicable, ECMO extra-corporeal membrane oxygenation, CRRT continuous renal replacement therapy, ARDS acute respiratory distress syndrome, RR respiratory rate, SpO2 peripheral oxygen saturation, PaO2/FiO2, PaO2 partial pressure of oxygen in arterial blood, PaCO2 oxygen inspired fraction, AV atrioventricular, AKI acute kidney injury, COPD chronic obstructive pulmonary disease, PaCO2 pressure of arterial carbon dioxide, GCS Glasgow coma scale, ICU intensive care unit

^†As reported in studies, not better specified; ^‡referred to patient with complication in exam
higher in severe cases ($P = 0.001$): severe cases were defined as critical cases presenting respiratory failure, shock, and/or multiple organ dysfunctions. Even more, severe cases were more likely to have comorbidities. Chen et al., in a retrospective study of 113 patients, aimed to relate demographic, clinical, and radiological characteristics between patients recovered versus deceased patients [17]. They found that cardiac complications were more frequent in non-survivor patients in comparison to recovered patients (association between complications and outcomes). In particular, the authors found that 77% of patients with a diagnosis of acute cardiac injury (defined on the basis of cardiac biomarkers and/or ECG alterations) died; half of these patients presented hypertension or cardiological disease in their medical history.

Heart failure (defined on the basis of age-related pro-BNP) was observed in 49% of dead patients: half of these patients presented hypertension or cardiological disease in their medical history. Shi et al., in a retrospective study of 671 patients, evaluated the clinical characteristics and the impact on outcome of cardiac complications in COVID-19 patients [44]. Cardiac injury was defined as an increase of cardiac biomarkers above the 99th percentile upper reference limit. Patients were divided into survivors and non-survivors. The cause of death was attributed to ACI in 30.6% of the patients. Patients with cardiac injury were older and with more comorbidities in comparison to COVID patients without cardiac injury ($P < 0.001$). Acute heart failure represented the cause of death in 19.4% of the patients. Du et al. retrospectively analyzed the risk factors and clinical features of 85 COVID-19 patients who died [22]. ACI was observed in 44.7% of the patients. Cardiac arrest represented 8.64% of cases of death. Acute coronary syndrome represented 4.94% of cases of death. Similar results were reported in the remaining included studies, with the percentage of acute cardiac injury varied from 12 to 55% [15, 27, 42, 53, 54, 56–58]. Contrarily, Wan et al. found that acute cardiac injury was observed in 7.4% of the cases; no
statistical difference was found between the percentage of acute cardiac injury in mild and severe forms [50]. The authors examined the clinical feature of COVID-19 patients and divided the enrolled patients into mild and severe forms (respiratory rate > 30 beats/minute, mean oxygen saturation < 93%, PaO$_2$/FiO$_2$ < 300).

The prospective international study by Dweck et al. reported data from 1216 echocardiographic examinations in COVID-19 patients [24]. The indications for echocardiographic evaluation were suspected left heart failure in 40%, elevated cardiac biomarkers in 26%, right heart failure in 20%, and ST-segment elevation in 9% of the cases. Chest pain and ST-segment elevation represented the indication for performing echocardiographic evaluation in 13% of the cases (14 patients). Severe impairment of the left ventricle was observed in 9% of the cases (112 patients) and of the right ventricle in 6%. New myocardial infarction was observed in 3% of the population examined [24]. Seven percent of these patients exhibited elevated levels of troponin and/or BNP. Similarly, the prospective study of Szekely et al. aimed to perform a comprehensive echocardiographic evaluation of COVID-19 patients [47]. One hundred patients were enrolled of whom 68% showed echocardiographic abnormalities: RV dilatation (39%), LV diastolic dysfunction (16%), and LV systolic dysfunction (20%). Troponin level above the 99th percentile was reported in 20% of the patients. Comorbidities were observed in 72% of the patients.

The retrospective study by Chen et al., on 54 patients, aimed to evaluate cardiac complications on COVID-19 patients and to identify possible risk factors [16]. Patients were divided into critical and severe forms of COVID-19 based on clinical evaluation (i.e., respiratory rate, peripheral oxygen saturation and gas exchange, respiratory failure, mechanical ventilation requirement, organ dysfunction, shock). An echocardiographic scan was performed in 31 patients: new-onset heart failure was observed in 20% of critically ill patients; 13.3% presented with right heart failure and pulmonary hypertension and 6.7% with left heart failure. Severe cardiac injury was found to be an independent risk factor predicting the critical status of COVID-19 patients (OR = 2.4, 95% CI 1.8–20.1, P = 0.4).

Concerning acute myocardial infarction, in the retrospective study of Stefanini et al., the authors evaluated the incidence, clinical presentation, angiographic findings, and outcome of 28 COVID-19 patients who underwent urgent coronary angiography for STEMI [46]. STEMI was defined according to ESC guidelines [65]. 71.4% of the population had hypertension in their medical history, 32.1% diabetes mellitus, 28.6% chronic kidney disease, and 10.7% previous myocardial infarction. In 85.7% of the cases, STEMI represented the cause of hospitalization. At echocardiographic evaluation, left ventricular ejection fraction < 50% was observed in 60.7% of the cases, 82.1% presented regional wall abnormalities, 10.7% diffuse hypokinesia, and 7.1% no abnormalities. On coronary angiography evaluation, 60.7% presented a culprit lesion needing revascularization, whereas 39.3% did not present coronary artery disease. No one underwent fibrinolysis. A follow-up evaluation reported that 39.3% of patients died, 3.6% were still in hospital, and 57.1% had been discharged. On the same aspect, Bangalore et al. detected 18 COVID-19 patients with ST-segment: in 8 patients, the diagnosis of myocardial infarction was confirmed (i.e., coronary angiography, echocardiography) [13]. The group of patients with myocardial infarction presented a high incidence of hypertension (86%), hypercholesterolemia (29%), and diabetes mellitus (43%) as risk factors. Even more, the echocardiographic evaluation showed a low ejection fraction in 88% of the cases and regional wall motion abnormality in 75% and a higher level of troponin and D-dimer. Six out of eight patients underwent coronary angiography: 5 patients were treated with PCI. In-hospital mortality occurred in 50% of patients with myocardial infarction.

To summarize, patients with acute cardiac injury seemed to be significantly older, with comorbidities, more likely to develop complications, and with higher mortality rates. Acute cardiac injury represented the prevalent cardiac complications observed in COVID-19 patients (from 20 to 45% of the patients). Acute cardiac injury was found to be an independent risk factor for severe forms of SARS-CoV-2 infection and an independent predictor of mortality.

**Takotsubo syndrome**

The evidence of cardiomyopathies was evaluated in six of the papers retrieved (as shown in Table 3): one international survey [24], one observational study [63], and four case reports [18, 34, 40, 45]. The evaluation of cardiological complications in patients with COVID-19 was the main aim of 5 studies [18, 24, 34, 40, 45].

In the international survey by Dweck et al., the author observed echocardiographic evidence of Takotsubo syndrome (TTS) in 2% of cases (19 patients), associated with an increase in troponins (10 patients) and BNP levels (5 patients) [24]. Similarly, Stöbe et al. performed an echocardiographic evaluation study on COVID-19 patients in order to characterize the cardiac abnormalities in this group of patients [63]. Interestingly, the authors performed myocardial deformation analysis, with the evaluation of global and regional circumferential and radial layer strain deformation. They found that the cardiac abnormalities were high in the COVID-19 patients included. The most common findings were a reduced longitudinal strain (71%), absence or dispersion of basal rotation (43%), and reduced circumferential strain in the
mid and basal segments (50%). The authors concluded that in the majority of the patients included the LV dysfunction observed was similar to “reverse basal Takotsubo like syndrome.”

Takotsubo was also described in three case reports [34, 40, 45]. In both cases, chest discomfort, elevation of troponin, and EKG alterations were observed with negative coronary angiography. Similarly, the woman was treated with medical therapy and was discharged at home after the resolution of echocardiographic abnormalities. In the clinical cases described by the Spanish and the Italian group, the authors observed an inverted TTS: akinesia of the basal segments of the left ventricle on echocardiographic evaluation [40, 45].

Myocarditis
Myocarditis complications were reported in twelve of the papers retrieved (as shown in Table 4): one international survey [24], two retrospective studies [19, 32], and nine case reports [21, 26, 28, 29, 31, 35–37, 55]. All the aforementioned studies aimed at analyzing cardiac complications in patients with COVID-19.

In the international survey of Dweck et al., the authors observed 35 cases of myocarditis (3% of the population studied) with an associated increase in troponin (19 patients) and BNP levels (13 patients) [24]. In the retrospective study by Deng et al., 14 cases (12.5%) of suspected myocarditis were observed [19]. The authors followed the statement from the American Heart Association for the diagnosis of myocarditis [66]. The patients with suspected myocarditis presented the following clinical characteristic:

- A mean age of 74 years
- Predominantly men (71.4%)
- Comorbidities: hypertension (42.6%), diabetes (28.6%), and coronary artery disease (21.4%)

Fourteen patients presented an increase in cardiac biomarkers (i.e., CK-MB and pro-BNP). Even more, 10 patients presented alteration in echocardiographic evaluation, 2 in EKG, and 2 in both exams. In comparison with 98 patients without suspected myocarditis, the authors observed a statistical difference for age, blood saturation of oxygen, shortness of breath, and respiratory rate at admission.

In the retrospective study of Kunal et al., the authors enrolled 108 patients with COVID-19 [32]. Myocarditis was classified based on the level of diagnostic certainty:

- Histological/immunohistological evidence
- Symptoms/EKG findings/cardiac biomarkers/TTE/cardiac MRI

However, no proven data on intra-myocytes active viral replication were found.

Pericardial effusion
Pericardial effusion was evaluated in five of the papers retrieved (as shown in Table 5): one international survey [24], three retrospective studies [16, 19, 32], and one case report [18]. All the aforementioned studies aimed at analyzing cardiac complications in patients with COVID-19 patients.

In the prospective international study by Dweck et al., cardiac tamponade represented the indication for performing echocardiographic evaluation in 2% of the cases (20 patients) [24]. Cardiac tamponade was confirmed in 1% of the cases.

In the retrospective study by Chen et al., echocardiographic evaluation was performed in 31 patients; pericardial effusion was observed in 5 critical patients and 1 severe case ($P < 0.01$). Pericardial effusion was found to be an independent risk factor predicting the critical status of COVID-19 patients (OR = 3.5, 95% CI 1.8–15.1, $P = 0.5$) [16]. Kunal et al. reported two cases of pericardial effusion (1.9%): one patient with moderate pleural effusion without cardiac tamponade [32]. In the study by Deng et al., pericardial effusion > 5 mm was observed in 19.6% (22 patients) with a statistically significant difference in the percentage of PE in patients with severe versus non-severe form of COVID pneumonia (28.3 vs. 6.7%, $P < 0.01$) [19]. In 13.4% of patients, the authors also observed signs of pulmonary hypertension (according to the definition of the American Society of Echocardiography and the European Society of Cardiology) [67, 68].

Arrhythmias
Arrhythmic complications were evaluated in thirteen of the papers retrieved (as shown in Table 6): one international survey [24], seven retrospective [15, 16, 19, 22, 25, 32, 56], one observational [54], two case reports [41, 49], and two case series [11, 38]. Nine out of eleven studies analyzed cardiac complications in patients with COVID-19 as first objective [11, 16, 19, 24, 25, 32, 38, 41, 49]; for four of these articles [11, 38, 41, 49], the development of arrhythmias was the primary outcome of the study.

In the prospective international study by Dweck et al., ventricular arrhythmia represented the indication for performing echocardiographic evaluation in 3% of the cases (38 patients); 33 of 38 patients presented echocardiographic alterations [24]. Contrarily, Yu et al. observed 9.3% of arrhythmic complications (21 patients) mostly represented by atrial fibrillation (%) [54]. Supraventricular tachycardia was observed in 2 patients whereas ventricular tachycardia was found in one patient. In the retrospective study by Chen et al., the authors described several ECG alterations and compared the percentage between severe and critical patients [16]:

- Sinus tachycardia 59% (23 patients) of severe patients versus 100% of the critical group ($P < 0.1$)
- Ventricular tachycardia 13.3% (2 patients) of severe patients versus 2.6% (1) of the critical group (no statistical difference)
- Premature beat 20.5% (8 patients) of severe patients versus 13.3% (2 patients) of the critical group (no statistical difference)
- Atrioventricular block 0% of severe patients versus 13.3% (2 patients) of the critical group (no statistical difference)
- Sinus bradycardia 5.1% (2 patients) of severe patients versus 6.7% (1 patient) of the critical group (no statistical difference)
- Atrial fibrillation 0% of severe patients versus 6.7% (1 patient) of the critical group (no statistical difference)

Remarkably, the authors stressed that they did not observe an association between tachycardia and body temperature or oxygen saturation.

Tachycardia was observed in 29.5 % of the cases (33 patients) in the retrospective study by Deng et al. [19]: no statistical difference was observed between severe versus non-severe forms of COVID pneumonia (P = 0.34). Zhang et al. reported 22 cases of arrhythmia complications in the severe form of COVID-19 patients (40% vs. 1.2%, P < 0.001) [56]. Du et al. reported 60% of arrhythmic complications; in 2.47% of cases, malignant arrhythmia represented the cause of death [22]. Cao et al. found arrhythmic complications in 38.9% of intensive care patients in comparison to 13.1% of non-intensive patients [15]. Guo et al. reported an incidence rate of 7% for VT and VF [25].

In the retrospective case series of Amaratunga et al., the authors highlighted bradycardia as a possible important complication of COVID viral infection [11]. Even more, they suggested that the onset of bradycardia in COVID patients has to be regarded as a possible manifestation of a serious cytokine storm. These patients required closer monitoring for possible cardiological sequelae. The authors also speculated on possible etiologists: hypoxia, inflammatory cytokine storm, and drug integrations. Remarkably, the four cases described presented sinus bradycardia, not associated with high changes in temperature; three out of the four patients were sedated with propofol or dexmedetomidine, but the bradycardia persisted even when the same drugs were discontinued. An important aspect to analyze was the association between bradycardia and hypotension; three patients required the use of vasopressors in order to maintain PAM > 65 mmHg.

Right ventricular dysfunction
Right ventricle dysfunction was evaluated in six articles retrieved (Table 7): two retrospective studies [16, 19], one prospective study [47], one international survey [24], 1 observational study [63], and one case report [55].

In the prospective international study by Dweck et al., right ventricle dysfunction was found during echocardiography evaluation in 313 patients (21%), with a mild to moderate impairment in 236 patients (19%) and a severe impairment in 77 patients (6%) [24]. From a morphological perspective, RV was dilated in 181 patients (15%), with D-shape left ventricle in 46 patients (4%). Elevated pulmonary artery pressure (PAPs) was found in 99 patients (8%). The independent predictors of RV failure in patients without pre-existing heart disease were suspected right heart failure (OR 2.65, 95% CI 1.88–3.75) and moderate (OR 2.34, 95% CI 1.32–4.29) or severe COVID-19 symptoms (OR 3.19, 95% CI 1.73–6.10).

In the retrospective study by Chen et al., echocardiographic evaluation was performed in 31 patients. Right ventricular dysfunction, with right heart enlargement/pulmonary hypertension, was observed in 2 critical patients, care; both patients died [16].

Comparing patients with severe and mild symptoms, St be et al. did not find a statistically significant difference in RV function [63]: global longitudinal strain (GLS) of the free wall was −26.6 ± 5.9% in severe cases vs. −27.5 ± 6.1 % in mild cases (P = 0.76). In four out of ten patients with severe symptoms, RV GLS was mildly reduced (between −17 and −23%), with a higher value of troponin T and NT-pro-BNP. Similarly, in two out of four patients with mild symptoms, RV GLS was mildly reduced (between −22 and −23%).

Szekely et al. evaluated right ventricular function analyzing RV fractional area change, tricuspid annular plane systolic excursion, systolic lateral annular velocity, and pulmonic flow acceleration time (AT) velocity [47]. RV dilatation was found in 39% of the patients and represented the most common echocardiographic pattern in COVID-19 patients. Increased RV end-diastolic area was significantly associated with mortality (1.14 [HR, 1.01–1.32]; P = 0.05 for 1 cm²).

Risk factors
The following risk factors were highlighted during the literature search:

- Hypertension: the majority of the article reported hypertension as one of the main risk factors in patients with COVID-19. Hypertension was observed in 55.6% of the COVID-19 included in the study of Shao et al. [42]. Cao et al. observed that ICU patients were more probable to suffer from comorbidities and found hypertension in 55% of the cases [15]. Chen et al. found that hypertension was more frequent in deceased patients in comparison to recovered (48% vs.24%) [17]. In the study of Zhang et al., hypertension was observed in 24.4% of the patients included, with a significant difference between
### Table 7: Characteristics and outcomes of retrieved trials for the outcome “Right ventricular dysfunction”

| Authors          | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex (M/F) | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Morphological RV alterations (treatment-control or n° pts) | Systolic dysfunction (treatment-control or n° pts) | sPAP (treatment-control or n° pts) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases - controls) |
|------------------|--------------------------|-----------------------------|---------------------------|-----------|-------------------------------------|-----------------------------|-------------------|-----------------------------------------------|-------------------------------------|---------------------------------|----------------------------------------|--------------------------------------|
| Chen et al. [60] | 57.6 (44.9–70.3)§        | 56.1 ± 135°                 | 61.7 ± 9.6°               | 36/18     | Hypertension (16)                   | Diabetes (25) Coronary heart disease (6) | NA                | Severe condition if: Respiratory distress, RR > 30 acts/min or SpO₂ < 93% rest or P/F < 300 | Failure (0–2)                         | Elevated (0–2)                   | AKI (18)                             | NA                                   |
| Deng et al. [62] | 65 (49–70.8)§            | 68 (57–77)§                 | 56 (39–67)§               | 57/55     | Hypertension (36)                   | Diabetes (19) Coronary heart disease (15) Atrial fibrillation (4) | COBD (4)          | None                                           | NA                                  | Mechanical ventilation (28) ECMO (3) | Death (14)                           | NA                                   |
| Dweck et al. [38] | 62 (52–71)§              | 64 (53–73)§                 | 60 (51–69)§               | 84/365    | Hypertension (445)                  | Diabetes (233) Ischemic heart disease (167) Heart failure (113) Valvular disease (80) | NA                | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | Dilated (181)                         | Mild to severe (313)                | Elevated (99)                        | NA                                   |
| Stibbe et al. [36] | 64 ± 19.1°               | 71 ± 15.2°                  | 41 ± 11.8°                | 14/4      | Hypertension (13)                   | Paroxysmal atrial fibrillation (4) Coronary artery disease (2) Dyslipidemia (4) Diabetes (5) Stroke (3) | Chronic kidney disease (7) COPD (1) | NA                                           | RV GLS mildly reduced (4–2) | None                                      | Mechanical ventilation (14) | NA                                   |
| Szekely Y et al. [47] | 66.1 ± 17.3°            | 65.9 ± 20°                  | 69.8 ± 16°                | 63/37     | Hypertension (57)                   | Ischemic heart disease (16) Congestive heart failure (7) | Chronic renal disease (10) Diabetes (29) Obesity (29) Asthma (7) Malignancy (5) | Acuity score | Dilated (39)                                      | RV/FAC reduced 38.8 ± 11 (10) | NA                                           | NA | NA                                   |
Table 7 Characteristics and outcomes of retrieved trials for the outcome “Right ventricular dysfunction” (Continued)

| Authors | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex (M/F) | Cardiologial comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Morphological RV alterations (treatment-control or n° pts) | Systolic dysfunction (treatment-control or n° pts) | sPAP (treatment-control or n° pts) | Other no cardiac complications (n° pts) | Outcome (n° pts or cases - controls) |
|---------|--------------------------|----------------------------|---------------------------|-----------|-----------------------------------|-----------------------------|------------------|----------------------------------------------------------|------------------------------------------|----------------------------------|-----------------------------------|----------------------------------|
| Zeng et al. [44] | 63+ NA NA 1/0 Smoke (1) Allergic cough (1) | NA | NA | NA | NA | NA | Cerebrovascular disease (11) | Atrial fibrillation (71) | | | | | |

Data are presented as real number*, percentage*, mean ± SD*, or median and (IQR)*

M male, F female, pts patients, TnT troponin T, TnI troponin I, BNP brain natriuretic peptide, NT-proBNP N-terminal pro-brain natriuretic peptide, EF ejection fraction, LVEDV left ventricular end-diastolic volume, NA not applicable, ECMO extra-corporeal membrane oxygenation, CRRT continuous renal replacement therapy, ARDS acute respiratory distress syndrome, RR respiratory rate, SpO2 peripheral oxygen saturation, P/F PaO2/FiO2, PaO2 partial pressure of oxygen in arterial blood, FiO2 oxygen inspired fraction, PaCO2 pressure of arterial carbon dioxide, AKI acute kidney injury, COPD chronic obstructive pulmonary disease, ICU intensive care unit, NIV noninvasive ventilation, HIV human immunodeficiency virus, IABP intra-aortic balloon pump, PCI percutaneous coronary intervention, EKG electrocardiogram, STEMI ST-elevation myocardial infarction, DIC disseminated intravascular coagulation, LBBB left bundle branch block

*As reported in studies, not better specified; °referred to patient with complication in exam
severe and non-severe forms of COVID-19 (47.3% versus 16.9%, \( P < 0.001 \)) [56]. In the study of Zhou et al., hypertension was observed in 30% of the patients included, with a significant difference between non-survivor and survivor (48% versus 23%, \( P = 0.0008 \)) [58]. Hypertension was significantly different in patients with cardiac injury in comparison with patients with no cardiac injury in the study of Shi et al. (59.8% versus 23.4%, \( P < 0.001 \)) [43]. Kunal et al. found that hypertension was the most common comorbidity (38%) [32], with a significant difference between non-survivor and survivor (\( P = 0.01 \)) and between patients that developed or not acute cardiac injury during in-hospital stay (\( P < 0.0001 \)). Univariate logistic regression analysis found that hypertension was a predictor of mortality (OR: 2.94; 95% CI: 1.23–7.00; \( P = 0.015 \)). Conversely, Du et al. found that hypertension was high (59.6%); however, the authors missed finding any statistical difference between ICU and non-ICU groups (\( P = 0.380 \)) [23]. Similarly, Huang et al. did not find any statistical difference between ICU and non-ICU groups (\( P = 0.93 \), hypertension in 15% of the cases) [27]. Wan et al. found hypertension in 9.6% of patients: the percentage of hypertension was similar between severe and mild forms of COVID-19 (10 vs. 9.4%) [50]. Finally, Xiong et al. found that hypertension was high in patients included (38.8%); however, the authors missed to find any statistical difference between severe and non-severe groups [52].

- Cardiovascular disease: Chen et al. found that cardiovascular disease was more frequent in deceased patients in comparison to recovered (14% vs. 4%) [17]. In the study of Zhang et al., cardiovascular disease was observed in 10% of the patients included, with a significant difference between severe and non-severe forms of COVID-19 (23.6% versus 5.4%, \( P < 0.001 \)) [56]. In the study of Zhou et al., coronary artery disease was observed in 8% of the patients included, with a statistically significant difference between non-survivor and survivor (24% versus 1%, \( P < 0.0001 \)) [58] [54]. Kuno et al. found that among 8438 patients with COVID-19, 8.6% had CAD, 8.1% peripheral artery disease, and 6.9% heart failure [33]. Patients with CAD, peripheral artery disease, or heart failure presented higher rates of mechanical ventilation and mortality in all age groups. In the retrospective study of Guo et al., the authors found that 35.3% of patients had a cardiovascular disease in their medical history (coronary heart disease, cardiomyopathy, hypertension) [25]. Mortality rates were 13.33% for patients without cardiac injury and 69.44% for patients with cardiac injury and cardiovascular disease in their medical history. Patients with cardiovascular disease were more likely to have myocardial injury during hospital stay. Coronary heart disease and chronic heart failure were statistically significantly different in patients with cardiac injury in comparison with patients with no cardiac injury in the study of Shi et al. (\( P < 0.001 \)) [43]. Coronary heart disease and chronic heart failure were statistically significantly different in the group of non-survivors in comparison with the survivor group in the study of Shi et al. (\( P < 0.001 \)) [44]. Contrary, Du et al. did not find any statistical difference between ICU and non-ICU groups (\( P = 0.349 \)) [23]. Cardiovascular disease was observed in 15% of the patients included in the study of Huang et al., and no statistical difference was observed between ICU and non-ICU groups (\( P = 0.32 \)) [27]. Chen et al. did not find a statistically significant difference in coronary artery disease between severe and critical forms (\( P = 0.75 \)) [16]. Deng et al. found coronary artery disease in 13.4% of the cases with not finding a statistically significant difference between severe and non-severe forms (\( P = 0.25 \)) [19].

- Cerebrovascular disease: Chen et al. found that cerebrovascular disease was more frequent in deceased patients in comparison to recovered (4% vs.0%) [17]. Cerebrovascular diseases were observed also in 13.5% of the patients in the study of Yang et al.; the incidence was higher in non-survivors in comparison to survivor groups (22 vs. 0%) [53]. Yu et al. found cerebrovascular disease in 6.6% of the patients [54]. In the study of Zhang et al., cerebrovascular disease was observed in 6.8% of the patients included, with a statistically significant difference between severe and non-severe forms of COVID-19 (20% versus 2.4%, \( P < 0.001 \)) [56]. Cerebrovascular disease was statistically significantly different in patients with cardiac injury in comparison with patients with no cardiac injury in the study of Shi et al. (15.9% versus 2.7%, \( P = 0.001 \)) [43]. Cerebrovascular disease and chronic heart failure were statistically significantly different in the group of non-survivors in comparison with the survivor group in the study of Shi et al. (12.9% versus 2.3%, \( P < 0.001 \)) [44].

- Diabetes: Chen et al. found that diabetes was more frequent in deceased patients in comparison to recovered (48% vs.24%) [17]. For Du et al., diabetes was observed in 22% of the patients included [22]. Similarly, Yu et al. found diabetes in 20.8% of the cases, 4.4% with organ damage and 16.4% without organ damage [54]. Xie et al. found that patients with diabetes had a higher prevalence of severe form (\( P = 0.032 \)) [51]. Kunal et al. found diabetes in 32.4% of the patients [32] with a statistically significant difference between non-survivor and survivor (\( P = \)
0.05) and between patients that developed or not acute cardiac injury during in-hospital stay ($P = 0.005$). Wan et al. found diabetes in 8.9% of patients: the percentage of diabetes was higher between severe and mild forms of COVID-19 (22.5 vs. 3.1%) [50]. Diabetes was observed also in 17% of the patients in the study of Yang et al.: the incidence was higher in non-survivors in comparison to survivor groups (22 vs. 10%) [53]. In the study of Zhou et al., diabetes was observed in 19% of the patients included, with a significant difference between non-survivor and survivor (31% versus 14%, $P = 0.0051$) [58]. Chen et al. found a significant difference in diabetes between severe and critical forms (33.3% versus 80%, $P < 0.01$) [16]. Diabetes was significantly different in patients with cardiac injury in comparison with patients with no cardiac injury in the study of Shi et al. (24.4% versus 12%, $P = 0.008$) [43]. Diabetes was statistically significantly different in the group of non-survivors in comparison with the survivor group in the study of Shi et al. (27.4% versus 13.1%, $P = 0.004$) [44]. Contrariwise, Xiong et al. found that diabetes was high in patients included (16.4%); however, the authors missed to find any statistical difference between severe and non-severe groups [52]. Diabetes was frequent in the multicenter observational study by Du et al. (31.2%); no statistical difference was observed between ICU and non-ICU groups ($P = 0.386$) [23]. Huang et al. found diabetes in 20%; however, the authors missed to find any statistical difference between ICU and non-ICU groups ($P = 0.16$) [27]. Deng et al. found diabetes in 17% of the cases with not finding a statistically significant difference between severe and non-severe forms ($P = 0.18$) [19].

- Chronic respiratory diseases: Chen et al. found that chronic respiratory diseases were more frequent in deceased patients in comparison to recovered (10% vs. 4%) [17]. Chronic respiratory disease was observed in 15.6% of the patients included in the multicenter observational study by Du et al. (31.2%); they observed a higher percentage of chronic respiratory diseases in non-ICU groups reaching a statistically significant difference ($P = 0.036$) [23]. Chronic respiratory diseases were observed also in 8% of the patients in the study of Yang et al.; the incidence was slightly higher in survivors in comparison to non-survivor groups (10 vs. 6%) [53]. Yu et al. found chronic respiratory diseases in 6.6% of the patients [54]. In the study of Zhou et al., chronic obstructive lung disease was observed in 3% of the patients included, with a statistically significant difference between non-survivor and survivor (7% versus 1%, $P = 0.047$) [58]. Arentz et al. found 33.3% of chronic obstructive pulmonary diseases, 28.6% of obstructive sleep apnea, and 9.1% of asthma in patients included [12]. Inversely, Deng et al. found chronic obstructive pulmonary disease in 13.4% of the cases; no statistically significant difference was found between severe and non-severe forms ($P = 0.53$) [19]. Shi et al. did not find a significant difference for chronic obstructive pulmonary disease in the group of non-survivors in comparison with the survivor group ($P = 1.0$) [44].

Due to the few cases included, it is difficult to draw any conclusion to the real impact of malignancy chronic kidney disease, chronic liver disease as risk factors on COVID-19 [17, 22, 23, 25, 27, 32, 44, 52, 54, 56–58, 63]. In one study, chronic kidney failure represented the most common comorbidities among COVID-19 patients (47.6%) [12]. Cancer was statistically significantly different in patients with cardiac injury in comparison with patients with no cardiac injury in the study of Shi et al. [43].

**Secondary outcome: cardiac complications and mortality**

We included 7 studies investigating 2115 patients in the meta-analysis [17, 25, 32, 43, 44, 53, 58]. The risk ratio (RR) was 0.20 (95% CI: 0.17 to 0.24; $P < 0.00001$, as shown in Fig. 3). Heterogeneity among the studies was significant ($I^2 = 0.75$). Performing subgroup analysis, for acute cardiac injury patients, we observed a RR of 0.19 (95% CI: 0.16 to 0.24; $P < 0.00001$ as shown in Fig. 3), in favor of survivor. Heterogeneity among the studies was high $I^2 = 0.80$. For acute myocardial infarction and myocarditis, it was possible to retrieve data only from one study [32].

**Discussion**

Emerging evidence showed that, besides acute respiratory disease, cardiac complications may also occur in COVID-19 patients with a severe impact on outcome [8]. Consequently, it is extremely important to further evaluate and share awareness regarding the correlation between COVID-19 and cardiovascular implications.

In our systematic review, we observed that the rate of patients suffering from an acute cardiac injury or myocardial infarction varied among the studies. This can be explained partially by the heterogeneity of the studies included. However, ACI represented the predominant cardiac complications in COVID-19 patients in several studies included (from 20 to 45% of the patients). Patients with acute cardiac injury seemed to be significantly older and with comorbidities. Patients with cardiac injury were more likely to develop complications during the hospital stay with higher mortality rates. ACI was found to be an independent risk factor for the severity of SARS-CoV-2 infection and an independent
predictor of mortality. In our meta-analysis, we found a statistically significant difference between non-survivor and survivor in patients with acute cardiac injury ($P < 0.0001$; $I^2 = 80\%$). Myocardial infarction, heart failure, and cardiogenic shock were also described in the literature, with a smaller incidence among COVID-19 patients. Due to the paucity of prospective studies with data mainly basing on case reports, it was not possible to draw any conclusion regarding Takotsubo, myocarditis, and pericardial effusion. Remarkably, the incidence rate of arrhythmia events during hospitalization varied widely among the studies (from 3 to 60\%). This can be explained by the wide difference of inclusion criteria between the studies. Several ECG alterations were described (i.e., sinus tachycardia, ventricular tachycardia, premature beat, sinus bradycardia, atrial fibrillation) at different stages of disease. The presence of arrhythmia should be evaluated also in the context of hypoxemia degree and in relation to cardiac, metabolic, and multi-organ deterioration. Analyzing the studies retrieved, it was not possible to draw any assumption regarding the possible association between arrhythmia and comorbidities. Hypertension seemed to represent the most common comorbidities in COVID-19 patients (from 30 to 59.8\%); however, the evidence regarding the relation between hypertension and severity of the disease and mortality was inconclusive. The prevalence of cardiovascular disease was high in this group of patients (up to 57\%); in particular, coronary artery disease seemed to be around 10\% of the cases. In the majority of the studies retrieved, patients with CVD had a higher prevalence of severe form, ICU admission, and higher mortality rates. Furthermore, diabetes emerged as an important risk factor in COVID-19 patients although the evidence is scarce. Due to the lack and the heterogeneity of the cases included, it was not possible to draw conclusions regarding the real role of cerebrovascular disease, chronic respiratory diseases, malignancy, chronic kidney disease, and chronic liver disease as risk factors on COVID-19.

Several physio-pathological mechanisms were proposed to explain the cardiovascular manifestations in COVID-19 patients (i.e., direct and indirect mechanisms): etiology is characterized by a complex interaction between virus, host responses, and underlying cardiac comorbidities [9]. Even if patients with several

| Study or Subgroup | Survivors Events | Total Events | Non survivors Events | Total Events | Weight | Risk Ratio M–H, Fixed, 95% CI | Risk Ratio M–H, Fixed, 95% CI |
|-------------------|-----------------|-------------|----------------------|-------------|--------|-------------------------------|-------------------------------|
| 1.1.1 Acute cardiac injury | 17 | 61 | 72 | 113 | 26.4% | 0.17 [0.10, 0.27] | |
| 1.1.1 Acute myocardial infarction | 3 | 78 | 1 | 30 | 0.5% | 1.15 [0.12, 10.66] | |
| 1.1.4 Myocarditis | 2 | 78 | 1 | 30 | 0.5% | 0.77 [0.07, 8.17] | |
| Total (95% CI) | 185 | 451 | 100.0% | 0.20 [0.17, 0.24] | |

Fig. 3 Forest plot for cardiac complications and mortality between survivors and non-survivors. The black diamond at the bottom of the graph represents the average effect size whereas the horizontal line represents the 95% confidence interval (CI). A random-effects model was used. The sample size, the overall effect, 95% CI, and heterogeneity are shown.
risk factors (i.e., CVD, diabetes, COPD) may be more susceptible to develop cardiac complications, cardiac abnormalities were also observed in patients without cardiovascular comorbidities.

Cardiac injury can be triggered by a number of direct and indirect mechanisms including viral injury and the interplay with host cells (COVID-19 spike protein (S), ACE2 receptor, host serine protease TMPRSS2, cathepsin B, and cathepsin L) [69]. Preliminary autopsy reports found T-lymphocytic infiltration, CD68+ macrophage infiltration, and viral particles within vascular endothelial cells of the heart in addition to diffuse vascular endothelial cell injury [29]. However, no evidence of viral replication has been found within the cardiomyocytes. Additionally, cytokine storms and systemic inflammatory syndromes and the dysregulation of host immune response may play a role [70], although it needs to be further clarified [71, 72]. Hypoxia related to respiratory failure represents another important role of cardiac injury through the same pathophysiological mechanism leading to type 2 myocardial infarction mechanism [73]. The consequent oxygen supply/demand mismatch is not only due to an inadequate oxygen reserve, but it is also due to the increased demand for oxygen and energy during the cytokine storms, systemic inflammatory syndromes, and dysregulation of host immune response. The loss of the normal balance between the pro- and anti-inflammatory system results in an uncontrolled activation of the inflammatory response, in an immune imbalance (involving both the innate and the adaptive immune response systems), and in a consequent inability of the host to limit the inflammation [74, 75]. IL-6 and catecholamines are responsible for the increase of core body temperature, heart rate, and cardiac oxygen consumption as well. The consequent increase of beat per minutes reduces the filling time with a consequent decrease in myocardial perfusion. Even more, systemic inflammatory response and the consequent release of several inflammatory mediators (i.e., cytokines, chemokines) lead to endothelial dysfunction with coronary artery spasm, thrombosis, and further decrease in heart blood supply. Both hypoxia and pro-inflammatory status lead to mitochondrial dysfunction, alterations of ion channels, and changes of autonomic autoregulation. Alteration of calcium channels and consequent reduction of intracellular calcium led to an impairment of the contractile activity of myocytes [76]. Additionally, reduced oxygen delivery, leading to tissue hypoxia, may have the potential to trigger signaling networks (i.e., hypoxia-triggered signaling pathways) with possible effects in tissue modeling processes and cardiovascular disorders. In particular, hypoxia-inducible factor-1α (HIF-1α) and HIF-2α are transcription factors responsible for the transcriptional cellular responses to hypoxia [77].

Coagulation abnormalities are frequent in COVID-19 patients with several consequences for the cardiovascular system. Depending on the severity of pulmonary embolism, the consequence for the cardiovascular system can range from worsen hypoxemia (with the aforementioned consequences) to right heart failure. Even more, the formation of occlusive thrombus can be observed in the coronary artery itself leading to infarction or inside the cardiac chambers [78]. In addition, electrolyte imbalances are known for their potential dangerous consequence on the cardiovascular system [79]. The renin-angiotensin system plays a central role in controlling fluid and electrolyte balance. This mechanism can partially explain the frequent electrolyte imbalance that has been described in COVID-19 patients. In particular, hyponatremia and hypokalemia are common in COVID-19 patients and may be used as a marker of severity for a rapid screen [80]. Finally, drug-related heart injury and drug interaction were described in COVID-19 patients. In particular, QT-interval prolongation has been observed with the use of hydroxychloroquine, azithromycin, and protease inhibitors [81] and interactions between antiviral agents and some antiarrhythmics and anti-coagulants were described [82]. Another important aspect to analyze is the effects of cardiac complications in COVID-19 patients on mortality. In our meta-analysis, we found a statistically significant difference of acute cardiac complications between non-survivor and survivor groups (P < 0.0001). These results have to be weighted on the high heterogeneity between the studies retrieved (I² = 80%). However, analyzing the Forrest plot is clear to notice the higher number of cardiovascular events in the non-survivors’ group in comparison to survivors. This aspect is worth to be underlined. Consequently, the cardiovascular complication in COVID-19 patients must be considered a priority during the clinical evaluation of this kind of patients.

We anticipated major limitations of this review: first of all, the heterogeneity in cardiac injury definitions. The authors of this systematic review reported the definition provided by the authors for each article retrieved. It is critical to stress further the importance to follow international consensus definition in order to reach evidence and avoid biases in patients enrollment and result interpretation. In the articles retrieved, acute cardiac injury was defined as an increase in serum levels of troponin T above the 99th percentile and/or new abnormalities in ECG/echocardiographic evaluations. In the 2018 “Fourth Universal Definition of Myocardial Infarction,” myocardial injury was defined as “Detection of an elevated cTn value above the 99th percentile URL” [73]. Acute cardiac injury is defined when concomitantly to myocardial injury a raise and/or fall of cTn values occurs. In case of a persistently elevated cTn level, cardiac injury is defined as chronic.
The authors described acute myocardial infarction as “acute myocardial injury with clinical evidence of acute myocardial ischemia.” Consequently, for the diagnosis of acute myocardial infarction, there is a need to observe, on top of ACI, at least one of the following symptoms of myocardial ischemia: ECG changes, development of Q waves, documentation of coronary thrombus, and TTE abnormalities [73]. However, the widespread use of a homogeneous and standardized definition allows comparison and trend analysis between studies over the time. The importance of a clear and internationally approved definition should be also stressed for myocarditis [83]. Approximately half of the studies retrieved used cardiac magnetic resonance evaluation to reach a diagnosis of myocarditis. However, only three articles referred to specific international guidelines/recommendations for the diagnosis of myocarditis.

Second, the long-term consequences of cardiac manifestations in COVID-19 patients remain basically uncertain due to the limited period of time for post-trial follow-up. A relatively short follow-up period may fail to evaluate the real impact of cardiac complications on outcome. However, follow-up represented a limitation to take into account. Third, we included several case reports and case series. Besides the debatable role of case reports in the era of evidence-based medicine, case reports present several interesting aspects not to be underestimated especially in the COVID-19 pandemic period. Case reports can have an important impact on clinical practice. Case reports can allow a rapid identification of a new disease or complications, consequently can represent an important warning signal, and can promote communication between the medical community. Observation to publication time is short, and this can lead to rapid detection of unusual or harmful clinical findings or complications. As a consequence, case reports can change clinical practice and stimulate the design of further studies. Nevertheless, there is a huge need of well-designed observational studies. Few studies were focused on a specific cardiac complication. Indeed, in order to reach evidence, it is vital to perform large well-designed observational studies aiming to investigate a specific aspect of cardiac complications, following clear and well-standardized definitions.

Conclusions
Acute cardiac injury represented the prevalent cardiac complications in COVID-19 patients. Patients with acute cardiac injury appeared to be significantly older, with co-morbidities, more prone to present complications, and with greater mortality rates. Arrhythmic complications have to be carefully considered by physicians in COVID-19 patients for the possible consequences and complications. Even if inconclusive, it seemed that the presence of coexisting medical conditions is prominent in COVID-19 patients. Few studies were focused on a specific type of cardiac complications. Indeed, in order to reach evidence, it is vital to perform large well-designed observational studies aiming to examine the prevalence of specific cardiac complications, following clear and well-standardized definitions.

Abbreviations
COVID-19: Coronavirus disease; ACE inhibitors: Angiotensin-converting-enzyme inhibitors; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; PRISMA: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses; MEDLINE: US National Library of Medicine database; CENTRAL: Cochrane Central Register of Controlled clinical studies; RCT: Randomized controlled trial; COPD: Chronic obstructive pulmonary disease; EKG: Electrocardiogram; TTE: Transthoracic echocardiogram; PaO2/FIO2: Ratio of arterial oxygen partial pressure to fractional inspired oxygen; PaO2: Arterial oxygen partial pressure; PCO2: Arterial carbon dioxide partial pressure; GCS: Glasgow Coma Scale; CRRT: Continuous renal replacement therapy; ACI: Acute cardiac injury; CV: Cardiovascular; OR: Odds ratio; CI: Confidence interval; ACE/ARB: Angiotensin-converting-enzyme inhibitors/angiotensin II receptor blocker; BNP: B-type natriuretic peptide; ARDS: Acute respiratory distress syndrome; RV: Right ventricle; LV: Left ventricle; LVEF: Left ventricular ejection fraction; EF: Ejection fraction; CI: Cardiovascular index; ESC: European Society of Cardiology; STEMI: ST-elevation myocardial infarction; LVED: Left ventricular end-diastolic pressure; PCI: Percutaneous coronary intervention; LAD: Left anterior descending artery; LVEF: Left ventricular ejection fraction; LVEF: Left ventricular ejection fraction; LCX: Left circumflex artery; RCA: Right coronary artery; MOF: Multi-organ failure; TTS: Takotsubo syndrome; CK-MB: Creatine kinase myocardial band; MRI: Magnetic resonance imaging; CT: Computed tomography; LVEDV: Left ventricular end-diastolic volume; PE: Pulmonary embolism; PAM: Mean arterial pressure; AT: Pulmonary flow acceleration time velocity; CVD: Cardiovascular disease; CAD: Coronary artery disease; cTn: Cardiac troponin; URL: Upper reference limit; S: Spike protein; HIF1-α: Hypoxia-inducible factor-1α

Acknowledgements
None

Authors’ contributions
BE: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. MF: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. BP: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. TG: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. CF: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. FF: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. CF: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. TG: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. BP: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. MF: concept and design, acquisition of data, interpretation of data, drafting/critical revision of the manuscript, and control and guarantee that all aspects of the work were investigated and resolved. None

Funding
None

Availability of data and materials
Not applicable
Declarations

Ethics approval and consent to participate
NA

Consent for publication
NA, original data

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56124 Pisa, Italy. 2Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. 3Department of Emergency-Covid Intensive Care, Azienda Ospedaliero Universitaria di Bologna - Policlinico “S. Orsola Malpighi”, Bologna, Italy. 4Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, Via Roma n. 67, 56126 Pisa, Italy. 5Department of Clinical-Surgical, Diagnostic and pediatric Sciences, University of Pavia, Via Alessandro Brambilla, 74, 27100 Pavia, Italy. 6Anesthesia and Intensive Care, Ente Ospedaliero Ospedali Galliera, Genova, Italy. 7Department of Anesthesia and Intensive Care, Ente Ospedaliero Ospedali Galliera, Genova, Italy.

Received: 20 December 2021 Accepted: 7 April 2022
Published online: 27 April 2022

References

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng J, Xu L, Holmes EC, Zhang YZ (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265–269. https://doi.org/10.1038/s41586-020-0208-3
2. Russo E, Brogi E, Gamberrini E, Agnoletti V (2020) COVID-19: a clinical and organizational crisis. Intern Emerg Med 15:897–899
3. Bolondi G, Russo E, Gamberrini E, Cirilli A, Meca MCC, Brogi E, Viola L, Bissoni L, Poletti V, Agnoletti V (2020) Iron metabolism and lymphocyte characterisation during COVID-19 infection in ICU patients: an observational cohort study. World J Emerg Surg 15(1):141. https://doi.org/10.1186/s13017-020-00323-2
4. Fiaccini G, Tricò D, Ribechni A, Forfori F, Brogi E, Lucchi M, Berrettini S, Bertini P, Guaracino F, Bruschini L (2021) Evaluation of the incidence and potential mechanisms of tracheal complications in patients with COVID-19. JAMA Otolaryngol Head Neck Surg 147(1):70–76. https://doi.org/10.1001/jamaoto.2020.4148
5. Bertini P, Forfori F, Bruschini L, Corradi F, Ribechni A, Brogi E, Guaracino F (2021) Percutaneous tracheotomy in COVID-19 critically ill patients: experience from 30 consecutive procedures. Int Arch Otorhinolaryngol 25(1):e135-e140. https://doi.org/10.1055/s-0040-1718528
6. Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan MA, Mascia M, Avenston A, Cilandiras S, Hussain S, Yoon J, Banyai K et al (2020) COVID-19: a cause of raised troponin and ECG changes. Lancet 395(10235):1516. https://doi.org/10.1016/S0140-6736(20)30912-0
7. Avila J, Long B, Holliday D, Gottlieb M (2021) Thoracic complications of COVID-19. Am J Emerg Med 39:213–218. https://doi.org/10.1016/j.ajem.2020.09.065
8. Babapoor-Farahkhan S, Gill D, Walker J, Raskehi RT, Bozorgnia B, Amanullah A (2020) Myocardial injury and COVID-19: possible mechanisms. Life Sci 253:117723. https://doi.org/10.1016/j.lfs.2020.117723
9. Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17(5):259–260. https://doi.org/10.1038/s41569-020-0360-5
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100
11. Amarantusa EA, Corwin DS, Moran L, Snyder R (2020) Bradycardia in patients with COVID-19: a calm before the storm? Circulation 126(6):e589. https://doi.org/10.1161/circulationaha.120.047559
12. Arentz M, Tim E, Kalf F, Lohandawala S, Riedo FX, Chong M, Lee M (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. Jama 323(16):1612–1614. https://doi.org/10.1001/jama.2020.024326
13. Bangalore S, Sharma A, Slotwiner A, Yatsik L, Harari R, Shah B, Ibrahim H, Friedman G, Thompson C, Alviar CL et al (2020) ST-segment elevation in patients with COVID-19 - a case series. N Engl J Med 482:2478–2480
14. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S (2020) COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 153(6):725–733. https://doi.org/10.1093/ajcp/aqaa062
15. Gao J, Hu X, Cheng W, Yu L, Tu W, Liu Q (2020) Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intern Med Care 46:851–853
16. Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, Zhu W, Di W, Ge J (2020) Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol 43(7):796–802. https://doi.org/10.1002/clc.23984
17. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H et al (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 368m1091
18. Dabbagh MF, Aurora L, D’Souza P, Weinmann AJ, Bhargava P, Basir MB (2020) Cardiac tamponade secondary to COVID-19. JACC Case Rep 2:135–139
19. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, Cheng Y, Yan I, Ping H, Zhou Q (2020) Suspected myocardial injury in patients with COVID-19 evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 311:116–121. https://doi.org/10.1016/j.ijcard.2020.03.087
20. Domínguez-Erquicia P, Dobarrow D, Raposeiras-Roubin S, Bastos-Fernandez G, Higüez-Romo A (2020) Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. Eur Heart J 41(22):2132. https://doi.org/10.1093/eurheartj/ehaa393
21. Doyen D, Moceri P, Ducrèux D, Dellamonna J (2020) Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet 395(10235):1516. https://doi.org/10.1016/S0140-6736(20)30912-0
22. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P et al (2020) Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med 211(13):1372–1379. https://doi.org/10.1164/rccm.202003-0543OC
23. Du RH, Liu LM, Yin W, Wang W, Guan LL, Yuan ML, Li Y, Hu Y, Li XY, Sun B et al (2020) Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China. Ann Am Thorac Soc 17(7):839–846. https://doi.org/10.1513/AnnalsATS.202003-225OC
24. Owen MR, Bulang A, Hahn RT, King B, Lee KK, Chapman AR, White A, Salvo SD, Sade LE, Pearce K (2020) Global evaluation of echocardiography in patients with COVID-19. Eur J Heart Cardiovasc Imag 21(9):940–958. https://doi.org/10.1002/ejcar.1718
25. Guo T, Fan Y, Chen Y, Men W, Xu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(7):811–818. https://doi.org/10.1001/jamacardio.2020.10172
26. Hu H, Ma F, Wei X, Fang Y (2020) Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 42(2):206
27. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical
